The Dynamics of Acute Inflammation by Kumar, Rukmini
THE DYNAMICS OF ACUTE INFLAMMATION
by
Rukmini Kumar
M.Sc. Physics, Indian Institute of Technology, Madras, 1999
B.Sc. Physics, Stella Maris College, Madras, 1997
Submitted to the Graduate Faculty of
the Faculty of Arts and Sciences in partial fulfillment
of the requirements for the degree of
Doctor of Philosophy
University of Pittsburgh
2004
UNIVERSITY OF PITTSBURGH
FACULTY OF ARTS AND SCIENCES
This dissertation was presented
by
Rukmini Kumar
It was defended on
September 2, 2004
and approved by
Prof. Carson Chow, Mathematics
Prof. David Jasnow, Physics
Prof. Donna Naples, Physics
Prof. Jonathan Rubin, Mathematics
Prof. Xiao-lun Wu, Physics
Dissertation Advisors: Prof. Carson Chow, Mathematics
,
Prof. David Jasnow, Physics
ii
THE DYNAMICS OF ACUTE INFLAMMATION
Rukmini Kumar, PhD
University of Pittsburgh, 2004
The acute inflammatory response is the non-specific and immediate reaction of the body
to pathogenic organisms, tissue trauma and unregulated cell growth. An imbalance in this
response could lead to a condition commonly known as “shock” or “sepsis”. This thesis
is an attempt to elucidate the dynamics of acute inflammatory response to infection and
contribute to its systemic understanding through mathematical modeling and analysis.
The models of immunity discussed use Ordinary Differential Equations (ODEs) to model
the variation of concentration in time of the various interacting species. Chapter 2 discusses
three such models of increasing complexity. Sections 2.1 and 2.2 discuss smaller models
that capture the core features of inflammation and offer general predictions concerning the
design of the system. Phase-space and bifurcation analyses have been used to examine the
behavior at various parameter regimes. Section 2.3 discusses a global physiological model
that includes several equations modeling the concentration (or numbers) of cells, cytokines
and other mediators. The conclusions drawn from the reduced and detailed models about
the qualitative effects of the parameters are very similar and these similarities have also been
discussed.
In Chapter 3, the specific applications of the biologically detailed model are discussed in
greater detail. These include a simulation of anthrax infection and an in silico simulation of
a clinical trial. Such simulations are very useful to biologists and could prove to be invaluable
tools in drug design.
Finally, Chapter 4 discusses the general problem of extinction of populations modeled
as continuous variables in ODEs is discussed. The average time to extinction and threshold
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are estimated based on analyzing the equivalent stochastic processes.
Keywords: Acute inflammation, ODE models, phase-space and bifurcation analyses, an-
thrax infection, in silico clinical trials, thresholds for extinction.
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1.0 INTRODUCTION
1.1 THE PROBLEM OF SYSTEMIC INFLAMMATION
The initial response of the body to an infection or to trauma is called the acute inflammatory
response. This is non-specific and is the first line of defense against danger. It consists
of a coordinated systemic and local mobilization of immune, endocrine and neurological
mediators (Janeway & Travers, 1997). In a healthy response, inflammation is activated,
clears the pathogen (in case of an infectious insult), begins a repair process and abates.
However, an improper immune response could result in prolonged uncontrolled systemic
inflammation that could lead to multiple organ dysfunction and death. In the case of an
infectious insult, this condition is known as “sepsis” and is the most prevalent cause of
mortality in Intensive Care Units (ICUs) (Tilney et al., 1973; Eiseman et al., 1977). Severe
sepsis is a common and frequently fatal condition with an estimated 750,000 cases annually
(1991) in the United States alone (Angus et al., 2001). Although much has been learnt about
the molecular and physiologic pathways of acute inflammation, this knowledge has not led
to many effective therapies (Cross & Opal, 2003).
1.1.1 Acute inflammation
The purpose of the acute inflammatory response is to clear the invading infectious agent,
dead and damaged tissue and to restore homeostasis, the normal state of the body. It often
starts off as a local response to the threat and if unresolved, spills over to result in systemic
inflammation. (Bone, 1996a).
Physiologically, acute inflammation consists of a web of interacting cells and mediators.
2
Phagocytic cells that engulf and kill bacteria, signaling proteins that can up- or down-
regulate inflammation (pro- and anti- inflammatory cytokines (signaling proteins)), effector
molecules, coagulatory mediators all play a role in this process. The process of inflammation
can itself cause tissue damage, hypotension and hypoperfusion of major organs. These also
contribute to exacerbating inflammation. Dysregulated systemic inflammation could thus
result in excessive tissue damage, hypotension and could eventually lead to multiple organ
failure and death.
Inflammation has traditionally been associated with redness, edema, fever and malaise.
The clinical symptoms of systemic inflammation have been characterized in order to iden-
tify and treat patients effectively. Two or more of the symptoms such as fever(> 38oC) or
hypothermia (< 36oC), hypotension (< 30 mm Hg), increased heart rate etc. are diagnos-
tic of the Systemic Inflammatory Response Syndrome or SIRS (Bone et al., 1992). These
definitions have also been updated to reflect changes in the understanding of the process
(Levy et al., 2003). Systemic inflammation that arises from infectious causes is called sepsis
and sepsis accompanied by organ dysfunction is known as severe sepsis. Shock is defined as
persistent hypotension despite fluid resuscitation.
Systemic inflammation and the ensuing morbidities were thought to be the result of an
excessive pro-inflammatory response. Several immuno-modulatory therapies targeted the
major pro-inflammatory players but were found to be ineffective. Currently, it is acknowl-
edged that anti-inflammatory mediators also play an important role in the pathogenesis of
inflammation and the imbalance between these processes contributes to the condition (Bone,
1996b).
The pathways of systemic inflammation and the ensuing clinical symptoms are virtually
indistinguishable in the cases of varying instigators such as bacteria, viruses, tissue trauma,
hemorrhage or more than one of the above insults. Thus the ultimate cause of death is
thought to be the improper immune response rather than the original instigator (Alberti
et al., 2002). Moreover, the common clinical symptoms defined above also reflect more
than one underlying physiologic state - e.g. recurrent infection, an inadequate response that
leads to uncleared infection or an exuberant response that leads to cleared infection but
unalleivated symptoms - could all be clinically classified as SIRS.
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Systemic inflammation and the ensuing morbidities are very much a product of modern
medicine. Before the discovery of advanced resuscitation techniques, patients could not be
kept alive long enough for the condition to fully unfold. Patients often died from blood
loss and severe infections before uncontrolled inflammation arose. With the advent and
improvement of antibiotics and organ support therapy, the condition has become increas-
ingly relevant (Bone, 1996a). The incidence of systemic inflammation is also expected to
increase with further advancement of medical technology and the increase in the susceptible
population - such as the elderly and HIV infected patients (Angus et al., 2001).
1.1.2 Pathogenesis of systemic inflammation
In this section the processes and mediators of the acute inflammatory response to a bacterial
infection are described briefly (see for example, (Janeway & Travers, 1997)). The growing
bacteria and sterile bacterial products (such as its cell wall, toxins released, bacterial coat)
activate the circulating white blood cells or phagocytic cells (neutrophils and macrophages).
They are “chemo-attracted” to the site of the infection and transform from “resting” cells to
“activated” cells. Phagocytic cells in their activated form can engulf and destroy bacteria and
damaged tissue. They also release cytotoxic chemicals which can oxidize and kill bacteria.
The activation and chemo-attraction of the phagocytic cells stimulates the production
of pro-inflammatory cytokines such as TNF-α and IL-1. (Cytokines are proteins secreted by
certain cells that act as inter-cellular mediators.) These cytokines have a rapid initial burst
and are found to be cleared within the first few hours in animal models. Their production is
shut down by rapidly acting anti-inflammatory cytokines such as IL-10 which are released in
response to them (Bone, 1996b; Janeway & Travers, 1997). TNF-α and IL-1 promote recruit-
ment and activation of phagocytes and also result in the second wave of slower cytokines.
These include the pro-inflammatory cytokines such as IL-6 and anti-inflammatory cytokines
such as TGF-β. It is important to note that even if the major functions of cytokines are
delineated in-vitro, they are often pleiotropic and their systemic effects might be different
than the determined local effects.
These inflammatory processes result in the release of cytotoxic substances, such as super-
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oxide (O−−2 ) and Nitric Oxide (NO), that aim to clear bacteria and dead tissue (Jaeschke
& Smith, 1997). It is postulated that the overwhelming release of these causes damage
to healthy tissues as well. The endothelial cells are thought to play a major role in the
pathogenesis of shock as they exacerbate inflammation and hypotension. Several other cas-
cades such as the complements and coagulatory mediators are activated in the process of
acute inflammation. It is hypothesized that the dysfunction in coagulation which results
in hypotension and hypoperfusion of major organs may contribute to death (Bone, 1996a).
The major mediators of the coagulation cascade are tissue factor, thrombin and activated
protein-C. Tissue factor is stimulated by bacterial toxins and IL-6 and causes the release
of thrombin, which is pro-inflammatory and contributes to tissue damage. Thrombin then
releases activated protein-C which is essentially anti-inflammatory and down-regulates the
coagulation cascade. The only FDA approved therapy for sepsis is Drotrecogin alpha which
adds activated protein-C to the body (Bernard et al., 2001).
In the case of a healthy outcome, inflammation results in the resolution of the original
insults and restoration of homeostasis. However, the processes of inflammation which cause
tissue damage, hypotension and hypoperfusion of major organs could lead to progressive
failure of major organs and eventually death. In fact, failure of the central nervous system,
lung and kidney failure and cardio-vascular shock are common causes of ultimate mortality
in ICUs (Alberti et al., 2002).
1.1.3 Therapies for systemic inflammation
The process of inflammation thus enhances and controls itself through a complex series of
redundant and pleiotropic systems which are delicately balanced. Current strategies in ICUs
are mainly supportive and include fluid resuscitation, vasopressors, blood transfusion and
mechanical ventilation (Vincent, 2002).
The search for the potential immune mediators to be modulated for alleviating the sepsis
syndrome has been ongoing for several years. Potential targets have included TNF-α, IL-
1, endotoxin and most recently activated protein-C. Of these, the sole target approved as
therapy for severe sepsis is activated protein-C, which reduced mortality by 6% compared
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with controls in clinical trials (Bernard et al., 2001).
Another major problem in tackling sepsis may lie in diagnosing the condition. In the clin-
ical setting, inflammatory states are defined by symptoms and few biological markers (Bone
et al., 1992). For example, Systemic Inflammatory Response Syndrome (SIRS) is a condition
characterized by elevated respiratory and heart rates, fever, and an abnormal white blood
cell count. The severity of sepsis is based on the presence of circulatory shock (low blood
perfusion) and organ failure (ACCP/SCC, 1992; Muckart & Bhagwanjee, 1997). Similarly,
treatment and support of these critically ill patients is largely based on clinical signs and a
few biochemical and hematological parameters.
The inflammatory response to an insult varies depending on several factors such as age,
co-existing morbidities, gender and genetic polymorphisms. The profile of cytokines in addi-
tion, depends on the time elapsed from the onset of infection. For the same insult in different
individuals, the response might be a healthy outcome and return to homeostasis, an insuffi-
cient response which suppresses but does not clear infection or overwhelming inflammation
and shock. The clinical symptoms for the negative outcomes might coincide but require
diverse treatment strategies. It is also possible that at different time points in the course of
disease, the same individual might be hyper-inflamed or immuno-suppressed. Therefore at
what time and to whom the therapy is administered are as important as what mediator is
being modulated.
Given the complexity of acute inflammation and the heterogeneity in its manifestation
in a population, it is highly unlikely that targeting a single mediator would prove to be an
effective strategy It is widely accepted that targeting a combination of mediators is likely to
be more successful (Bone, 1993; Cross & Opal, 2003). Also, different treatment strategies
might be required depending on the individual response to the insult.
1.2 MOTIVATION AND OUTLINE OF THE THESIS
The acute inflammatory response thus consists of a complex sequence of events that could
result in systemic inflammation and death. Despite a wealth of knowledge about the individ-
ual processes, treatment strategies are mostly supportive and effective targets for immune-
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modulation remain elusive. One reason for the lack of effective treatments against sepsis
may be that the complex nature of the inflammatory response renders the effect of targeting
isolated components of inflammation difficult to predict. The need for a systems based the-
oretical understanding of the sepsis syndrome has been emphasized (Tjardes & Neugebauer,
2002; Buchman et al., 2001) and such an understanding could be provided by mathematical
modeling.
Even simple dynamical models can capture essential features of the system and provide
intuition about its design. But predictions from such simple models are often too generic to
be useful to biologists. The strategy used in this thesis, is to study models of varying degrees
of complexity, each limited to answering a specific set of questions. The smaller models
provide qualitative understanding of the dynamics and also facilitate in understanding the
larger, more complex models. Such a complex model capturing the behavior of several specific
immune mediators has also been constructed. These models and the common dynamics
conserved among them are presented in Chapter 2.
The common dynamics and paths to “health” and “shock” are highlighted using a simple
Lotka-Volterra type 2-dimensional predator-prey model with a positive feed-back term in
the predator equation. This model is then expanded to 3 dimensions by adding another
equation to model the feed-back. The terms in the 3-d model are p, a growing pathogen,
m, the early immune response (predator) and l, the late immune response which forms a
positive feed-back loop with m. This model expands on the dynamics of the 2-d model and
simulations and bifurcation analyses reveal health, shock and additional negative outcomes
and the parameters that affect these outcomes. The reduced models were constructed to
understand the dynamics of the global model, which follows in detail the time-course of
several immune mediators and their interactions. This model is constructed based on well
established mechanisms of the pathogenesis of the disease and shows the health and the
negative outcomes shown by the 3-d model. Bifurcation analyses reveal similarities in going
from one outcome to the other. These models represent a new systematic understanding of
the mechanisms of acute inflammation and the pathways to shock. The important role that
later feed-back loops play in the pathogenesis of sepsis is emphasized.
Although the scope for analysis is limited in large models, simulations from them are very
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useful in evaluating physiological hypotheses and for in silico experimentation when data
is otherwise scarce. In Chap. 3 two such applications of a biologically detailed model are
presented. A model reproducing the time course of immune-mediators in anthrax infection
is presented. This is essentially a modification of the model presented in Chap. 2 to account
for the specific effects of anthrax bacterium. Simulations predicting the effectiveness of
a vaccine therapy are discussed. In this case, the evaluation of such a vaccine in human
trials is clearly unethical and predictions from such a model are likely to be very useful.
The second application is an implementation of a clinical trial evaluating the efficacy of
an anti-TNF antibody as a therapy for sepsis. This therapy was attempted but failed to
meet standards of efficacy in a randomized clinical trial (Abraham et al., 1998). As our
study shows, several factors can influence the efficacy of a drug such as timing and dosage of
therapy and patient population to which the therapy is administered. In an in silico clinical
trial, there is complete control and knowledge of the variables involved and this could lead
to significant insight. Future trials can also be designed with knowledge gained from such
models and could result in more optimal use of resources. (Drs. Gilles Clermont and Yoram
Vodovotz were major contributors in the building and understanding of the global model
and the ensuing modifications.)
The models discussed above are deterministic ODE models and have limitations in cap-
turing the real stochastic process. In Chap. 4, the effect of fluctuations at low concentrations
is examined. In a deterministic equation, decaying populations cannot become extinct in
finite time. Chapter 4 attempts to use a stochastic description of the processes when the
population numbers are small and calculate a threshold of extinction, below which the pop-
ulation may be considered to be extinct. The strategy used is to predict an average time
to extinction from a simple one dimensional population decay and examine its usefulness
in a more complicated scenario of interacting populations (such as a predator-prey model).
Several other techniques have been used to understand extinction in deterministic models
and Chap. 4 attempts to provide yet another approach to study this problem.
8
2.0 DYNAMICS OF ACUTE INFLAMMATION - 3 MODELS OF
INCREASING COMPLEXITY
This chapter attempts to understand the dynamics of the acute inflammatory response to in-
fection by using ODEs and the techniques of dynamical systems. Three models of increasing
complexity are presented. All the models obey mass-action kinetics in well-mixed volumes.
The simplest is a 2-dimensional model that captures only the essential bi-stability between
“healthy” and “septic” states and is followed by a 3-dimensional model that captures the bi-
stability and other clinically relevant negative outcomes as well. Bifurcation analysis on the
parameters of these models suggests the importance of the various interactions and provides
global understanding about the behavior of the system. A larger, more biologically accurate
model is also presented in Section 2.3. This model captures the detailed dynamics of various
mediators. However, the essential dynamics predicting the pathway to sepsis remains the
same in all three models.
Numerical simulations and bifurcation plots in this chapter were generated with XP-
PAUT (Ermentrout, 2002).
2.1 SEPSIS IN TWO DIMENSIONS
A minimal model of sepsis should have the following properties: for some insults, the
pathogen is completely eliminated and the system is returns to a “healthy” state and for
other insults the system reaches a a shock state where the immune mediators remain elevated
and never return to rest. Here, a two dimensional model is constructed that captures these
effects.
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In its most simplified description, the immune response to infection can be represented
by a Lotka-Volterra type predator-prey model where the prey represents for instance, the
bacteria that invade the system and the immune-cells are represented by the predator. This
yields the system
dp
dt
= kpp− kpmmp (2.1)
dm
dt
= kmpmp− kmm. (2.2)
This model represents a pathogen growing at rate kp and is ingested when it meets an
immune cell at rate kpmm. The immune cell is activated on contacting the pathogen at rate
kmpp and has a natural deactivation rate km. The behavior of this model can be explained
by phase-plane analysis. The fixed points are p = 0,m = 0 which is a saddle point and
p = km/kmp,m = kp/kpm which is a center. Irrespective of the parameters (as long as they
are all positive), any initial condition results in an oscillation around the center. Hence this
model cannot capture the dynamics of sepsis.
However, replacing (2.2) by
dm
dt
= kmpmp− kmm+ kfm2. (2.3)
results in a minimal model. This additional positive feedback introduces an additional fixed
point p = 0,m = km/kf which is a saddle if kf < (kpmkm)/kp and an unstable node otherwise.
The center of the previous system (2.1,2.2) becomes p = (1/kmp)(kfkp/kpm),m = kp/kpm and
is an unstable spiral (as long as 0 < kf < (kpmkm)/kp. See Appendix 2.5).
The phase-plane of this model with two sample trajectories is shown in Figure 2.1. One
of the trajectories loops around the unstable spiral point and remains close to p = 0 before
spiraling out to m = ∞ and the other trajectory goes directly out to m = ∞ without
spiraling. The latter is interpreted as the septic trajectory where immune mediators remain
elevated. The former is interpreted as healthy behavior. This is because when p gets small
enough, the approximation of p as a continuous variable breaks down. In this regime, the
discreteness of p is important and when p falls below a value representing a single pathogen
particle it can be considered to be eliminated. A stochastic model would be the correct
description for small particle numbers. For ODE models, p can never be reduced to zero
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in a finite time. Thus, for the models in this chapter, unstable spirals that take p close
to 0 are interpreted as healthy behavior. We propose that there is an effective threshold
representing a single pathogen particle below which, on average, the pathogen population
can be considered to be eliminated and this is discussed in detail in Chapter 4.
Thus, a positive feed-back in the m equation ensures the bi-stable behavior that we are
trying to capture. For large positive feed-back (kf ≥ (kpmkm)/kp), the unstable spiral is
no longer in the positive quadrant and no further oscillations are possible. Then all initial
conditions run away to m = ∞ or sepsis is the only possible outcome of the system. The
positive feed-back also ensures the complete elimination of the pathogen and avoids the
Lotka-Volterra oscillations seen in the system (2.1,2.2) which do not (in general) take p close
to 0. The claim made is that the pro-inflammatory positive feed-back is the crucial feature
of the acute inflammatory response that ensures elimination of pathogen and the strength of
this feed-back controls the predisposition of a system to sepsis. This very feature is observed
in the next two models as well.
Realistically, the pathogen is not expected to grow in an uncontrolled fashion in the
absence of immune cells. A competition for resources limits the growth and Equation (2.1)
is changed to reflect that.
dp
dt
= kpp− kpmmp− ksp2 (2.4)
Now, the model system (2.4,2.3) has an additional fixed point p = kp/ks,m = 0 which is
stable when km > (kmpkp)/ks and a saddle otherwise (see Appendix 2.5). The unstable spiral
of the previous model is changed to a slightly different location, p = (km− kfm∗)/kmp,m∗ =
(kpkmp − kmks)/(kmpkpm − kfks), but its instability still depends only on kf .
The above analysis is motivated by reasonable biological assumptions and simplicity in
modeling. An interesting aside is that the simple predator-prey model (2.1,2.2) can also be
modified by adding a positive feed-back term to the p equation instead of logistic saturation:
dp
dt
= kpp− kpmmp+ θp2. (2.5)
In this system (2.5,2.2), the only fixed point in the positive quadrant is p = km/kmp,m =
(1/kpm)(θkm/kmp + kp) which is an unstable spiral as long as θ > 0. In such a model, with
pathogen exhibiting extra growth on collisions (which is not usually observed biologically)
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and no feed back in the immune system, all initial conditions lead to unstable spirals and
thus the pathogen is always eliminated and there is no risk of sepsis. However, in addition
to being implausible, pathogens with other growth characteristics would not be eliminated.
Appendix 2.5 discusses the behavior of the two dimensional model in greater detail.
In the above modeling scheme, unstable spirals in the phase-plane are interpreted as
healthy behavior. A model where healthy behavior is instead represented by a stable fixed
point can also be constructed. For instance,
dp
dt
= kpp− kpmmp− k1(p− p0)p+ k2(p− ps)3p (2.6)
dm
dt
= kmpmp− kmm+ k3(m−m0)m− k4(m−ms)3m (2.7)
is a system where (p0,m0) could be the stable healthy fixed point and (ps,ms) the stable
septic fixed point. This model requires the pathogen to have a very specific (and unrealistic
growth profile). The model that we have presented has simpler biological interpretations
and does not demand any special properties from pathogen other than what is considered
to be its essential behavior.
2.2 A 3-D MODEL OF ACUTE INFLAMMATION
In this section, a simple 3-dimensional model of the inflammatory response to infection is
discussed. This model includes a third variable to provide a saturating positive feed-back to
the early immune response replacing the kfm
2 term in the 2-d model. Although the essential
dynamics do not change, an independent variable modeling late immune response is a better
approximation of reality. Positive feed-back mechanisms that enhance the pro-inflammatory
environment (such as phagocytic cells activated by immune-mediators (macrophages, neu-
trophils activated by TNF-α,IL-1); early immune-mediators promoted by later mediators
(TNF-α promoted by HMGB-1 etc.) are well documented processes of the acute inflamma-
tory response (Janeway & Travers, 1997; Bone, 1996a; Wang et al., 2001). The 3-d model
also exhibits various states which can be more readily identified with clinically relevant be-
havior. The diverse scenarios that arise are clearly defined and the ambiguous terminology
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Figure 2.1: The phase-plane for the 2-d model (2.1,2.3) showing “healthy” and “shock”
trajectories and the stable manifold that separates them. The red curves (marked with
horizontal arrows) correspond to conditions when dp
dt
= 0 (p = 0 and m = kp/kpm) and the
black curves (marked with vertical arrows) correspond to conditions when dm
dt
= 0 (m = 0
and p = (km − kfm)/kmp). The fixed points are at the intersections of black and red curves
and the direction of flow along a curve reverses at fixed points. The phase-space for a typical
set (kp = 1.0, kpm = 1.0, kmp = 0.5, kf = 0.2, km = 1.0) of parameters is shown. The stable
and unstable manifolds are shown in thicker lines. A typical healthy trajectory and sepsis
trajectory shown in dotted lines.
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of “sepsis” is avoided in this section. The model can show the following behavior: a healthy
response where pathogen is cleared and the body returns to homeostasis, recurrent infection
where inflammation is inadequate and the pathogen cannot be completely eliminated, persis-
tent infectious inflammation where the pathogen levels and inflammation are high, persistent
non-infectious inflammation where pathogen is cleared but inflammation persists and severe
immuno-deficiency where pathogen has grown to saturation but the inflammatory response
is very low. The model suggests that “sepsis” is a multifaceted disease and narrowly targeted
interventions are unlikely to succeed.
The unstable spiraling trajectory which represents healthy behavior in the 2-d model
is also present here and the spiraling trajectories are formed through sub-critical Hopf bi-
furcations. The runaway persistent inflammation trajectory is controlled by a saturating
term and hence persistent inflammation is a stable fixed point in this model. Additionally,
immuno-suppressed and recurrent infections are exhibited in the 3-d model which have no
clear analog in the 2-d model. Through a systematic analysis of the influence of parameters,
more detailed conclusions can be drawn about the acute inflammatory response.
In acute inflammation, an infectious pathogen triggers early pro-inflammatory responders
which attempt to kill the pathogen. The early inflammatory mediators then activate later
inflammatory mediators which can further excite the early mediators. This is the basis
of the model which consists of three variables: 1) a pathogen p, which is an instigator
of the innate immune response; 2) an early pro-inflammatory mediator m, which can be
thought of as representing the combined effects of immune cells such as macrophages and
neutrophils together with early pro-inflammatory mediators such as TNF-α and IL-1; 3) a
late pro-inflammatory mediator l which represents a late pro-inflammatory feedback. This
is a combined effect of cytokines such as IL-6, HMGB-1 and stimulatory effects of tissue
damage and dysfunction.
The model is as follows:
dp
dt
= kpp(1− p)− kpmmp (2.8)
dm
dt
= (kmpp+ l)m(1−m)−m (2.9)
dl
dt
= klmf(m)− kll (2.10)
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where
f(m) = 1 + tanh
(
m− θ
w
)
, (2.11)
θ is an activation threshold and w is an activation width. All the variables and parameters
are non-negative. The pathogen p obeys logistic growth and is killed when it interacts with
m. The presence of p or l and m will stimulate the growth of m which also has an intrinsic
death rate. This growth saturates as m increases towards unity mimicking the effects of cell
depletion and anti-inflammatory cytokines. The late mediator l is recruited by m through
a sigmoidal coupling function (2.11) and is cleared with the rate of kl. The parameters that
determine strength of the lm interaction term, the saturating parameters in the p and m
equation and the decay rate of m are used to scale p,m, l and t. In summary, the dynamics
obey predator-prey dynamics with a delayed response.
2.2.1 Dynamics of the model - Numerical examples
The model (2.8-2.10) exhibits behavior reminiscent of what is observed in clinical settings.
Given an initial condition of p > 0, m > 0 and l > 0, p grows, inducing m and l to grow
and attempt to eliminate p. Depending on initial conditions and parameters, the ensuing
orbits either approach stable fixed points or undergo oscillations, each having a physiological
interpretation. In (2.9) a non-zero positive initial value for m is necessary to generate an
inflammatory response. The background level of late mediators is given by l0 = (klm/kl)f(0)
and is non-zero for the present choice of parameters. Both these properties are consequences
of the particular choice for the form of the model and not essential for the qualitative results
found.
As discussed in the previous section, the unstable spiral is interpreted as healthy behavior
by introducing a threshold for pathogen level. When p falls below this threshold, it is
considered to be completely cleared. Numerical examples are considered for various values of
kpm, kmp, and klm. In Section 2.2.2, it is shown that these are natural bifurcation parameters
of the system. The other parameters are fixed at kpg = 3, kl = 1, θ = 1 and w = 0.5. The
effects of varying the parameters θ and w are shown in Appendix 2.6.2.1.
A healthy response to infection as seen in Figure 2.2 corresponds to an orbit that spi-
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rals outwards so that p falls below threshold during the oscillation. The pathogen is then
completely cleared which allows the inflammatory response to relax back to rest.
In Figure 2.3, the same parameters are used but the initial pathogen load is higher so
that instead of returning to background levels, the inflammatory mediators are over-excited
and remain elevated. This is related to a state of persistent non-infectious inflammation
where even though the pathogen is cleared, the inflammatory response does not abate. In
the model, this state is a fixed point but in a real organism if this condition continued, it
would eventually lead to multiple organ failure and death (Reyes et al., 1999).
Starting again from a healthy situation, if the pathogen susceptibility to the host’s de-
fenses (kpm) is decreased, persistent infectious inflammation is observed where the inflam-
matory response is high but the pathogen still cannot be cleared as seen in Figure 2.4. This
condition is equated with a severe septic state where both infection and inflammation are
uncontrolled. In this case the damage caused by both the pathogen and inflammation are
disrupting body function and if unabated death will result. Patients with systemic inflam-
mation, with and without documented infection, are observed in clinical settings (Alberti
et al., 2002).
If the recruitment rate of l (klm) is reduced, the healthy response can be turned into
one of recurrent infection as seen in Figure 2.5. (Changes in other parameters could also
lead to recurrent infection as seen in the next section). In this case, low levels of infection
persist indefinitely. This could be likened to infection with tuberculosis, yeast infections
or low-grade bacterial infections that persist for long periods of time (Beatty et al., 1994).
Although, a host could survive this state for a long duration it may eventually succumb.
Finally, in Figure 2.6, the activation rate of m due to p (kmp) is very weak, a state of
immuno-suppression or immuno-deficiency is observed where the pathogen grows to satura-
tion and does not elicit any response from the body. This could happen if the immune-system
had already been compromised by previous infection or trauma and then the organism is
re-infected. Opportunistic bacterial and fungal infections have been observed in immuno-
suppressed patient populations such as HIV infected patients, the elderly and those with
organ transplants (Schultz et al., 2001).
These five scenarios are the only possible outcomes in this 3-d model.
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Figure 2.2: Time courses of p, m and l for the healthy response. Orbits with the p elimination
threshold (solid line) and without (dotted line) are shown. With the threshold (set at
p0 = 0.0005), when p drops below p0, p is set to zero andm and l return to background values.
Without the threshold, the orbits spiral outwards. Parameters used are kpm = 30, kp =
3, kmp = 25, klm = 15, kl = 1. Initial conditions are p(0) = 0.01,m(0) = 0.05, l(0) = 0.539.
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Figure 2.3: In persistent non-infectious inflammation, p is eliminated but m and l remain
elevated. Parameters used are kpm = 30, kp = 3, kmp = 25, klm = 15, kl = 1. Initial conditions
are p(0) = 0.2,m(0) = 0.05, l(0) = 0.539.
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Figure 2.4: In persistent infectious inflammation, p cannot be eliminated andm and l remain
elevated (as in severe sepsis). Parameters used are kpm = 3, kp = 3, kmp = 25, klm = 15, kl =
1. Initial conditions are p(0) = 0.01,m(0) = 0.05, l(0) = 0.539.
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Figure 2.5: In recurrent infection, p is low and m and l remain above background values but
not very high (as in a low-grade infection). Parameters used are kpm = 30, kp = 3, kmp =
25, klm = 5, kl = 1. Initial conditions are p(0) = 0.01,m(0) = 0.05, l(0) = 0.179.
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Figure 2.6: In severe immuno-deficiency, p grows to saturation and m and l remain low or
absent. Parameters are kpm = 30, kp = 3, kmp = 0.4, klm = 15, kl = 1, p(0) = 0.01,m(0) =
0.05, l(0) = 0.539.
2.2.2 Dynamics of the model - Fixed Points and Bifurcations
These various regimes and transitions are best understood by examining the fixed points
and associated bifurcations of the model (2.8-2.10). The fixed points satisfy the following
conditions:
0 = p
[
p− 1 +
(
kpm
kp
)
m
]
(2.12)
0 = m
[
m− 1 +
(
1
kmpp+ l
)]
(2.13)
l =
klm
kl
f(m) (2.14)
Substituting (2.14) into (2.13) and rearranging gives
0 = m
[
p− 1
kmp
(
1
1−m −
klm
kl
f(m)
)]
. (2.15)
Three natural parameters that appear in the fixed point conditions, (2.12) and (2.15) are
considered: a ≡ kpm/kp, kmp, and b ≡ klm/kl. These three parameter combinations represent
the pathogen susceptibility to m compared to its growth rate (i.e. inverse of the pathogen
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Figure 2.7: Projection of fixed-point conditions onto the p-m plane. Projected directions
of field-flow are also marked. The red curves (marked with horizontal arrows) correspond
to conditions when dp
dt
= 0 (p = 0 and (2.16)) and the black curves (marked with vertical
arrows) correspond to conditions when dm
dt
= 0 (m = 0 and (2.17)). The fixed points are
at the intersections of black and red curves and the direction of flow along a curve reverses
at fixed points. The projection of the phase-space for a typical set of parameters is shown.
FP 1 and FP 4 are saddles. FP 3 is a spiral which is stable or unstable based on the actual
values of the parameters. FP 5 is a stable fixed point. FP 2 (not shown) is also a saddle in
this case.
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virulence), the activation rate of early responders m due to p, and the effective recruitment
rate of l due to m, respectively.
The intersections of conditions (2.12) and (2.15) give the fixed points of the system. The
dependence of the fixed points with the parameters is best observed as a projection in the
p −m plane as shown in Figure 2.7 where the fixed point conditions (2.12) and (2.15) are
plotted. Lines p = 0 and m = 0 are unaffected by changes in parameters. The line
p = 1− am (2.16)
is affected only by a and sweeps across the p−m plane as a is decreased. The curve
p =
1
kmp
(
1
1−m − bf(m)
)
. (2.17)
is affected only by the immune parameters b and kmp. It drops below p = 0 as b is increased.
Changing kmp affects the height and angle at which (2.17) intersects (2.16). Note that the
formation of FP 3 which undergoes Hopf bifurcations in Figure 2.7 is reminiscent of the
oscillations in the 2-d phase-plane in Figure 2.1. The p = 0 and m = 0 nullclines ensure that
all trajectories which start in the positive quadrant stay in it.
There are five fixed points which have been labeled from FP 1 to FP 5. FP 1 is given
by p = 0, m = 0, and l = (klm/kl)f(0). This fixed point is always unstable because the
pathogen is growing. FP 2 is given by p = 1, m = 0, l = (klm/kl)f(0) and may be interpreted
as a severely immuno-deficient state. Here the pathogen has grown to saturation, but there
is no early immune response and the late response remains at the background level. This
point is stable when the early immune response is very weak as shown in Appendix 2.6.1.2.
FP 4 and FP 5 arise from a saddle node bifurcation when p = 0 in (2.17). This can
be achieved by increasing b from zero as seen in the bifurcation plot in Figure 2.10. FP 4
is always unstable and never represents any physiologically relevant scenario. When stable,
FP 5 represents the persistent non-infectious inflammation fixed point. FP 3 is given by the
intersection of the line (2.16) with the curve (2.17). FP 3 could represent healthy, recurrent
infection or persistent infectious inflammation states, depending on parameter values. Below,
the three parameter combinations a, kmp and b are varied and the bifurcation plots are
examined.
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In the healthy scenario, a is large enough so that FP 3 is an unstable spiral and FP 5
is the only stable node (kpm = 20 in Figure 2.8). In this case, initial conditions close to
FP 3 undergo oscillations that take the pathogen below the elimination threshold and are
interpreted as healthy trajectories. A higher pathogen initial condition for the same set of
parameters takes the trajectories directly to FP 5 and this behavior is interpreted as persis-
tent non-infectious inflammation. This is similar to the trajectories seen in the phase-plane
of the 2-d model in Figure 2.1. When a is decreased, the slope of line (2.16) decreases and
it sweeps through FP 4 rendering it unstable through a transcritical bifurcation. However,
p is negative and thus FP 3 becomes unphysical (kpm = 10 in Figure 2.8). Hence FP 5 is the
only stable fixed point for all initial conditions in this regime. As a is decreased further FP
3 crosses FP 5 and they exchange stability through another transcritical bifurcation. FP 3
then becomes the only stable fixed point and is the global attractor for all initial conditions.
As expected, starting from a healthy scenario, the outcome of the system becomes more
and more severe with decreasing pathogen susceptibility (i.e. increasing effective pathogen
virulence). If we were to increase susceptibility a starting from the healthy scenario, FP
3 changes into a stable spiral surrounded by an unstable limit cycle through a subcritical
Hopf bifurcation. Now, trajectories within the unstable limit cycle spiral into the stable
fixed point FP 3 resulting in recurrent infection and unstable spiral trajectories outside the
unstable limit cycle will eventually dip below threshold and be interpreted as healthy. As FP
5 is still the attractor when the initial p orm is very high, this set of parameters could lead to
three different outcomes based on the initial conditions (kpm = 40 in Figure 2.8). Increasing
a further, increases the radius of the unstable limit cycle until it undergoes a homoclinic
bifurcation when it collides with FP 1. Here FP 3 is a stable spiral and only recurrent
infection is supported. The model therefore predicts that pathogen clearance is not possible
for a range of high pathogen susceptibility. However, as susceptibility is increased much
further, FP 3 gets closer to the origin so that oscillations around it take p below threshold
and may be interpreted as healthy.
Varying kmp, the strength of the early response, does not affect the stability or position
of FP 5, the persistent non-infectious inflammation point. Decreasing kmp takes a healthy
state to a state where healthy and recurrent infection co-exist and finally to one of recurrent
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infection only as shown in Figure 2.9. Decreasing kmp below 1 − (klm/kl)f(0) makes FP 3
collide with FP 2 (the severely immuno-deficient state where p grows to saturation and m
and l remain at background values). In a transcritical bifurcation, FP 2 becomes the stable
fixed point of the system and FP 3 becomes unphysical since m < 0. Increasing kmp from
the healthy value reduces the value of p in FP 3 - this reduces the range of initial conditions
for healthy behavior. However, for even very large values of kmp, FP 3 is an unstable spiral
with complex eigenvalues supporting healthy behavior for initial conditions starting close to
FP 3.
Varying the strength of the late response, b affects both FP 3 and FP 5. As b is decreased,
FP 3 undergoes a sub-critical Hopf followed by the homoclinic bifurcation of the unstable
limit cycle similar to the above cases (Figure 2.10). FP 4 and FP 5 are created in a saddle-
node bifurcation when the curve (2.17) intersects p = 0 by increasing b. However, there is
also an upper limit to b beyond which healthy behavior is not supported. The curve (2.17)
is below zero when it intersects (2.16) and FP 3 is unphysical. Thus when the late response
is too high, persistent non-infectious inflammation is the only possible outcome.
In the preceding, although the behavior of the system has been examined by mostly
varying only one parameter at a time, it gives us a picture of the global dynamics of the
system. Given the strong nonlinear saturation in the dynamics, orbits can either approach
a fixed point, a limit cycle, or a strange attractor. Given that FP 1 and FP 4 are always
unstable and FP 2 is stable only when kmp is very low, this leaves FP 3 (or stable limit
cycles around it) and FP 5 as the only candidates for global attractors. Ideally however,
FP 3 should be an unstable spiral or be surrounded by an unstable limit cycle, so that
oscillations around it can be interpreted as healthy behavior.
This gives an explanation for why healthy behavior always entails the risk of uncontrolled
inflammation. In order for the pathogen to be cleared, an unstable spiral that can take p
below threshold is required. However, if it were not for the (externally imposed) elimination
threshold the orbit would eventually end up at some attractor and persistent non-infectious
inflammation is the global attractor. Conversely, if the curve (2.17) has not yet intersected
p = 0 to form FP 4 and FP 5 (no persistent inflammation fixed point), FP 3 or a stable
limit cycle around it (recurrent infection) is the global attractor.
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There is a possibility that FP 3 could undergo a supercritical Hopf bifurcation (see
Appendix 2.6.1.3) which leads to a stable limit cycle around it. However, this is generically
interpreted as recurrent infection because fine tuning would be required to ensure that the
limit cycle takes p below threshold. Although, not possible in this model, a strange attractor
might occur in higher dimensional models. It is unlikely given the large amounts of negative
feedback and dissipation in the system. However, even if it were to exist, it may still not
lead to a healthy situation as p may never be eliminated or the early and late inflammatory
mediators could stay elevated albeit in a chaotic manner.
Physiologically, this implies that in order to completely rid the body of a pathogen, the
inflammatory response must respond strongly and remain elevated for a long enough time.
If it responds too weakly, then the pathogen persists. If it abates too quickly, then there will
be recurrent oscillatory infection. However, if it responds too strongly and too persistently
then there is a risk that it will be self-sustaining even after the pathogen is cleared. Thus,
there is a trade-off between being able to eliminate pathogens completely and risking non
abating inflammation. In Appendix 2.6.2, the parameter ranges where a healthy response is
possible are calculated.
In the next section, 2 parameter bifurcation plots are discussed which shed more light
on the dynamics of the model.
2.2.3 2 parameter bifurcations
The two bifurcations that are crucial in determining the behavior of the system are - the
saddle-node bifurcation which results in the creation of the persistent inflammation fixed
point and the sub-critical Hopf bifurcation which results in unstable oscillations which are
interpreted as healthy.
In this section, bifurcation plots varying the three main parameters, a, kmp and b(klm/kl)
are examined. The generic saddle-node and Hopf bifurcations are followed by varying two
parameters (a & b and kmp & b) at a time. It is noted that once the saddle-node bifurcation
creates the stable persistent inflammation fixed point, for all higher parameter values, the
system is susceptible to persistent inflammation. For a parameter range on either side of the
24
0 20 40 60
kpm
0
0.2
0.4
0.6
0.8
1
m
0 0.5 1
M
-0.5
0
0.5
1
P
FP 4
Unphysical
Healthy Oscillations
FP 5
FP 3
FP 4
<-- Increasing kpmFP 3
FP 5
FP 3
FP 4
FP 3
Figure 2.8: Bifurcation plot showing outcome as kpm and hence a = kpm/kp is increased.
For low kpm, FP 3 interpreted as persistent infectious inflammation is the only fixed point of
the system. As kpm is increased to ≈ 2.7, FP 5 (persistent infectious inflammation) becomes
the attractor of the system. FP 3 becomes unphysical and moves leftward in the p-m plane
(see inset). At kpm ≈ 11, FP 3 undergoes a transcritical bifurcation with FP 4, becoming
physical again. It is an unstable spiral, oscillations around which are interpreted as healthy.
On further increasing kpm, FP 3 undergoes a subcritical Hopf bifurcation and is surrounded
by an unstable limit-cycle, oscillations around which are interpreted as healthy. Trajectories
within the limit-cycle, which spiral into FP 3, are interpreted as recurrent infection. Healthy
behavior is lost to a homoclinic bifurcation at kpm ≈ 57. For large kpm, FP 3 and FP 5
are bistable (i.e. recurrent infection and persistent non-infectious inflammation are possible
outcomes of the system). (Inset : In the p-m plane, line (2.16) sweeps across the plane
causing the above bifurcations.)
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Figure 2.9: Bifurcation plot showing outcome as kmp is increased. For very low kmp(< 0.5),
FP 2 is stable and is interpreted as the severely immuno-deficient state. As kmp is increased,
FP 3 becomes stable through a transcritical bifurcation and recurrent infection is a possible
outcome of the system. As kmp is increased further FP 3 undergoes a subcritical Hopf
bifurcation (kmp ≈ 22). Oscillations around the unstable limit cycle surrounding FP 3 are
interpreted as healthy and are lost through a homoclinic bifurcation (kmp ≈ 9). Trajectories
within the limit-cycle spiral into FP 3 and are interpreted as recurrent infection. Beyond
the Hopf bifurcation (kmp > 22), FP 3 remains an unstable spiral, up to very large kmp
(kmp ≈ 2000) and oscillations around FP 3 are interpreted as healthy. On varying kmp,
only the position and eigenvalues of FP 3 are changed. FP 5 remains unaffected which
is interpreted as persistent infectious inflammation and remains a possible outcome of the
system. If curve (2.17) is shallow enough (b was small enough) so that FP 5 is not yet
created, then FP 3 remains the stable global attractor through changes in kmp. (Inset :
In the p-m plane, FP 3 varies in position and stability as (2.17) varies, causing the above
bifurcations. FP 5 remains unaffected.)
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Figure 2.10: Bifurcation plot showing outcome as klm or b = klm/kl is increased. For low
klm, FP 3 is a stable spiral representing recurrent infection. As klm is increased, FP 4 and 5
are created through a saddle-node bifurcation at klm ≈ 7 and the persistent non-infectious
inflammation is now a possible outcome. At klm ≈ 14, FP 3 undergoes a subcritical Hopf
bifurcation and is surrounded by an unstable limit cycle. The oscillations around the unstable
limit cycle are interpreted as healthy behavior and trajectories inside the limit cycle spiral
into FP 3 and are interpreted as recurrent infection. Healthy behavior is lost at klm ≈ 10
due to a homoclinic bifurcation. Beyond the Hopf bifurcation, healthy oscillations are still
supported by FP 3 which is now an unstable spiral. At klm ≈ 21, FP 3 meets FP 4 and
becomes unphysical through a transcritical bifurcation (as its p < 0). Beyond this point, FP
5 is the only stable attractor and persistent non-infectious inflammation is the only possible
outcome of the system. (Inset : In p-m plane, (2.17) descends as klm is increased causing
the above bifurcations.)
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sub-critical Hopf line, healthy behavior is supported. A homoclinic bifurcation at one end
and a transcritical bifurcation on the other end limit the range of healthy oscillations. Both
of these bifurcations are non-generic. This analysis reinforces some of the main conclusions
of the previous section. Bifurcation plots varying the parameters of the coupling curve θ and
w are also examined.
In Figs. 2.11, 2.12, the effect of varying the strength of early (kmp) and pathogen virulence
(kpm) with late response (b), on the saddle-node and Hopf bifurcations is shown. In both
cases, the saddle-node bifurcation that results in the creation of the persistent inflammation
fixed point is dependent only on the strength of late inflammation (b). The Hopf bifurcation
is influenced by all parameters. In Fig. 2.12, the line of Hopf bifurcations continues to the
“left” of the saddle-node bifurcations. These Hopf points (klm <≈ 7) are super-critical and
cannot be generically interpreted as healthy behavior. Thus, we still claim that the risk of
persistent inflammation is retained to ensure complete elimination of pathogen.
In the above analyses, the parameters that determine the shape of the coupling curve
between m and l, f(m) are kept fixed (θ = 1 and w = 0.5). These parameters affect both
the Hopf and saddle-node bifurcations. Parameter θ sets the threshold where l is activated
by m and parameter w gives the steepness of recruitment. Figure 2.14 shows the coupling
curves at various values of w and θ and the codim-2 saddle-hopf bifurcation obtained when
all other parameters are kept fixed. w and θ less than 1 result in the maximizing the range
of klm in which healthy behavior is observed as shown in Fig. 2.13.
2.2.4 Discussion of the 3-d model
This simple model of acute inflammatory response to infection shows the various negative
outcomes that arise from improper inflammatory response. These scenarios of persistent
inflammation (with and without infection), immuno-suppression and recurrent infection have
all been observed in critically ill patients (Alberti et al., 2002; Bone, 1996a). Vastly different
therapeutic strategies are called for to deal with the diverse negative outcomes. Although
strict correspondence with clinical reality is difficult to establish because of the simplicity of
the model, the model behavior is classified into the same broad categories.
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Figure 2.11: A 2 parameter bifurcation plot that varies the strength of early and late inflam-
matory mediators and follows the saddle-node bifurcation that gives rise to the persistent
inflammation fixed point. Only the strength of the late mediators (same b, as long as θ and
w remain the same) affects this bifurcation.
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Figure 2.12: A 2 parameter bifurcation plot that varies the strength of early and late inflam-
matory mediators and follows the saddle-node bifurcation that gives rise to the persistent
inflammation fixed point. Only the strength of the late mediators (same b, as long as θ and
w remain the same) affects the saddle-node bifurcation. The Hopf bifurcation is affected by
both parameters. The Hopf for parameter values klm <≈ 7 is super-critical.
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Figure 2.13: Bifurcation plots that vary coupling parameters θ and w with the strength of
late inflammatory mediator klm. θ = 1.0 and w = 0.5 are used for the simulations. These
values result in a larger range of klm where healthy behavior is supported.
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Figure 2.14: A 2 parameter bifurcation plot that varies θ and w (darker circles : klm = 10,
lighter circles : klm = 30). For large w and θ, the two bifurcations coalesce. Representative
coupling curves, f(m) = 1 + tanh (m−θ)
w
for specific values of w and θ are shown in the inset
(Curve 1 w = 0.2, θ = 0.2; Curve 2 w = 0.5, θ = 1.0; Curve 3 w = 2.0, θ = 2.0). w = 0.5
and θ = 1.0 are the values used in the analysis.
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The model has a rich bifurcation structure and exploring it allows us to understand how
changing parameters can take the system from one outcome to another. This model shows
that in order to have a healthy response to infection the virulence of the pathogen cannot
be too strong or too weak, the early pro-inflammatory response cannot be too weak, and the
late response cannot be too strong or too weak.
The effect of the strength of early and late pro-inflammatory responses is examined
and this model suggests that only the strength of the late pro-inflammatory wave governs
predisposition towards a state of persistent inflammation. This is similar to the predictions
from the even simpler 2-d model. No matter how exuberant the early wave may be, only
controlling the feedback from the late wave can determine whether the outcome is healthy
recovery or uncontrolled inflammation. Thus we predict that any therapy for persistent non-
infectious inflammation must target the slow pro-inflammatory mediators. In this model, as
in the 2-d model, a strong late-inflammatory response ensures elimination of pathogen but
introduces the risk of persistent inflammation.
Experiments have found that survival was improved in infected mice when the moderately
slow cytokine IL-6 was reduced (Riedemann et al., 2003). However, if too much IL-6 was
removed then there was a detrimental effect. This result is consistent with the predictions of
the 3-d model in that a small reduction lowered the possibility of a sustained inflammatory
response but lowering it too much precluded the possibility of eliminating the bacteria.
Evidence also has suggested that down-regulating HMGB-1, a late acting pro-inflammatory
mediator might be a potential target for anti-sepsis therapies (Wang et al., 2001). Activated
Protein-C which has been recently approved for treatment, is also partially a late anti-
inflammatory agent (Bernard et al., 2001). Previous therapeutic attempts have mostly
focused on down-regulating the early pro-inflammatory mediators and as predicted by the
model have not shown great effectiveness (Abraham et al., 1998; McCloskey et al., 1994).
On the other hand, if the patient is suffering from persistent infectious inflammation, then
therapies must be aimed at both reducing the pathogen load and the late pro-inflammatory
response. In this case, timing of the therapies may be important. It would be necessary to
reduce the bacterial load first before reducing the inflammation.
Conversely, low pathogen virulence or a weak immune response can lead to low level
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persistent or recurrent infection. Other theoretical models of infection have similar predic-
tions. Persistence of the tuberculosis bacterium Mycobacterium tuberculosis at low densities
for extended periods has been suggested to be the result of slow growth rates (Antia et al.,
1996). Similarly, a down-regulated immune response to Helicobacter pylori bacteria has been
suggested to result in its persistent colonization of the human stomach (Kirschner & Blaser,
1995). In the clinical setting, patients in the ICU with decreased host defenses are suscep-
tible to hospital-acquired infections (Schultz et al., 2001). These infections which may be
easily resolved in a healthy individual might result in unresolved inflammation and prove
fatal to a compromised individual. Immuno-stimulatory therapy might be effective in such
a situation.
The model shows that sepsis should be considered as a set of distinct physiological
disorders that require separate therapies even though they may have overlapping symptoms.
Categorizing septic states based on levels of bio-markers rather than clinical symptoms would
be the first step in addressing this problem and effort is ongoing in that direction (Levy et al.,
2003; Marshall et al., 2003).
2.3 A GLOBAL MODEL OF ACUTE INFLAMMATION
The models discussed in the previous sections are simple and offer general predictions about
the design of the inflammatory response. Often, however, results from such models are not
specific enough to be of immediate use in understanding complex biological systems. Larger,
more complex models incorporating the biological details are being increasingly used to make
more specific predictions (Polidori & Trimmer, 2003; An, 2001). Detailed models are often
limited by the amount of accurate biological information and data available to design them.
However, they can still be used effectively to gain useful information.
The model discussed in this section is a detailed representation of the processes of acute
inflammation. The model reproduces time courses of immune mediators, qualitatively similar
to those found in literature. This model can be used to track the time course of specific
mediators in response to an insult and specific times and doses of interventions may be
suggested to optimize the effectiveness of a given therapy (Kumar et al., 2001; Vodovotz
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et al., 2002). Results from such a model are more valuable to biologists and clinicians than
reduced models as the predictions are specific and encompass a variety of mediators.
In this section, the model and its features are discussed and in Chapter 3, its specific
applications are elaborated upon.
2.3.1 Features of the model
The model consists of 17 equations and captures the behavior of several key mediators using
ordinary differential equations. Spatial homogeneity is assumed for simplicity and the medi-
ators are assumed to interact with each other based on the mean field approximation. The
underlying assumption is that the time courses of mediators shown by the model represent
their concentration in the bloodstream. The effect of systemic inflammation on individ-
ual organs or the binding of effectors on cell surfaces by receptors are not modeled and no
predictions of such details are made.
The initial instigators of the immune response are the growing pathogen or sterile
pathogen products. The model is based on a generic gram negative bacterium that releases
endotoxins. An unstable spiraling trajectory formed through Hopf bifurcations (Figs.2.20,
2.21) represents healthy behavior in the global model. Unlike the reduced models, in the
simulations of the global model, the oscillating trajectories are clamped using a Heaviside
function. The growing pathogen term (Eq.2.39 and Eq.3.3) is multiplied by H(p−p0) where
p0 is an arbitrarily set low threshold. This ensures that the pathogen does not re-grow from
very low quantities.
The components of the immune system that are modeled are: the first responders which
are the phagocytic cells (neutrophils and macrophages), generic early (similar to TNF-α)
and late pro-inflammatory cytokines (similar to IL-6), a generic anti-inflammatory cytokine
(similar to TGF-β), oxidizing molecules that can kill pathogen and also cause tissue damage
(nitric oxide NO and oxygen free radical O−−2 ) and components of the coagulation cascade
(tissue factor, thrombin and activated protein-C). The model also includes equations for
global tissue dysfunction and blood pressure. Tissue dysfunction is caused by the pro-
inflammatory elements in the model and enhances inflammation itself. In general, elevated
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tissue dysfunction and low blood pressure are interpreted as a negative outcome whereas
background tissue dysfunction and blood pressure are interpreted as the healthy state. The
components of the model with brief descriptions are listed in Appendix 2.7.1.
The interactions modeled are as follows. Resting macrophages (Mr) are activated (ac-
tivated macrophages are represented by Ma) directly by growing pathogen (P ) and sterile
pathogen products (Pe). Neutrophils (N) also respond directly to these instigators. These
interactions occur at a systemic level where the stimuli enter the circulation and activate cir-
culating monocytes and neutrophils (Parker & Watkins, 2001). Activated neutrophils reach
compromised tissue by migrating along a chemoattractant gradient (Bellingan, 1999). Once
activated, macrophages and neutrophils enhance inflammation by producing and secreting
effectors that activate these same cells and also other cells, such as endothelial cells. Pro-
inflammatory cytokines - tumor necrosis factor (TNF ), interleukin (IL)-6 (IL6), promote
immune cell activation and pro-inflammatory cytokine production (Freeman & Natanson,
2000) These are included as the effects of the TNF and IL6 terms in the model.
The concurrent production of anti-inflammatory cytokines counterbalances the actions
of pro-inflammatory cytokines. In an ideal situation, these anti-inflammatory agents serve to
restore homeostasis. However, when over produced, they may lead to detrimental immuno-
suppression (Bone, 1996a; Pinsky, 2001; Volk et al., 2000). The model includes slow-acting
anti-inflammatory activity such as active transforming growth factor-β1 (TGF-β1), soluble
receptors for pro-inflammatory cytokines, and cortisol (Resting anti-inflammatory molecules
represented by Cr and activated molecules represented by Ca). It is noted that while acti-
vated TGF-β1 only has a lifetime of a few minutes, latent TGF-β1 is ubiquitous (Roberts &
Sporn, 1996) and can be activated either directly or indirectly by other slower agents such
as IL-6 or NO (Luckhart et al., 2003; Villiger et al., 1993; Vodovotz et al., 1999).
Pro-inflammatory cytokines also induce macrophages and neutrophils to produce free
radicals. In this model, NO derived from inducible NO synthase, iNOS (NOd) is directly
toxic to bacteria and indirectly to host tissue (Nathan & Hibbs, 1991; Babior, 2000; Johnson
& Billiar, 1998). The actions of superoxide (O−2 ) and other oxidative mechanisms (Babior,
2000) of the pro-inflammatory agents are also accounted for. In the model, the actions of
these products can cause direct tissue dysfunction or damage and this induced damage can
36
incite more inflammation by activating macrophages and neutrophils (Jaeschke & Smith,
1997). However, NO can also protect tissue from damage induced by shock (Florquin et al.,
1994; Harbrecht et al., 1992; Park et al., 1996), even though overproduction of this free
radical causes hypotension (Johnson & Billiar, 1998).
In endotoxemia, the model assumes that Lipopolysaccharide (LPS) (represented by Pe)
enters the bloodstream and incites a system-wide response (Beutler, 2000). LPS is cleared in
approximately one hour (Maitra et al., 1981; Ruiter et al., 1981). Circulating neutrophils are
activated directly and produce TNF (Djeu et al., 1990). The newly produced TNF combines
with LPS to activate macrophages that then secrete pro-inflammatory cytokines including
TNF, IL-6. (Cavaillon, 1994). Activated neutrophils, macrophages, and endothelial cells
produce NO through iNOS (Bogdan, 2001). The model assumes that locally produced NO
is eventually detected as the measured serum end products NO2-/NO3-, and this process
depends on the differential induction of eNOS and iNOS in various organs over time (Rees
et al., 1995; Santak et al., 1997). In order for TNF to rise and fall within a few hours as
it does in Fig. 2.15, the model required an inhibitory agent to suppress TNF production.
This was accounted for by saturating mechanisms (Bogdan et al., 1991; de Waal Malefyt
et al., 1991) and other slow anti-inflammatory cytokines including IL-6. Previous work has
indicated that IL-6 may exert both pro- and anti-inflammatory properties (Opal & DePalo,
2000). The anti-inflammatory action is assumed to be mediated by inducing or activating
TGF-β (Villiger et al., 1993) on the surface of neutrophils and macrophages, as has been
shown for cytokines such as interferon-γ (Chong et al., 1999).
This model is a very incomplete representation of all the processes of inflammation.
However, it captures many of the main features of acute inflammation, and can give new
insights into the complex interactions of the process. The interactions described in the model
are well documented and widely accepted in the biological literature. Their mathematical
forms are often based on estimates and documented relative strengths of interactions. There
are 100 rate constants or parameters in the model. Of these, 72 determine the strength
of interactions. 20 parameters are used to determine strengths and timings of intervention
which are not used to run the “base-line” case. 7 determine the thresholds and slopes for
hill- type interactions, 1 parameter is used to scale time to correspond to literature values.
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Of the 72 rate constants, some values and ranges of parameters are obtained directly from
literature and others are estimated based on relative strengths of interactions and in order to
satisfy base-line model behavior. There is uncertainty in the actual values of the parameters
that could influence the interpretations from the model. The values of the mediators are
not calibrated directly to data and only qualitatively follow expected behavior. Therefore
the units in which the mediators are expressed is arbitrary. However, time is marked in
hours. The set of mediators chosen to model is also subjective and arguably the role of early
anti-inflammatory cytokines has been underestimated. However, the variables chosen also
represent the major players which could not have been ignored.
Despite the various limitations explained above, the model is robust to small parameter
changes and is a useful systemic description of acute inflammation. Several meaningful
predictions, both intuitive and non-intuitive have been obtained from this model, some of
which are discussed below. This model can be used to test hypotheses about the interactions
and test the systemic effect of modulating specific mediators.
2.3.2 Simulations
The features for which this model was trained are summarized below. The healthy state,
persistent non-infectious inflammation and persistent infectious inflammation were required
to arise on increasing pathogen growth rate. Persistent inflammation was characterized by
elevated levels of immune mediators, tissue dysfunction and low blood pressure. The time
courses of early and late pro-inflammatory cytokines and nitric oxide were modeled according
to time courses obtained in the general biological literature. The response of the immune
system to sterile pathogen toxins was also used to determine some rate constants.
In the case of a moderate pathogen, healthy behavior is expected. In this model a
heaviside function is used to cut off pathogen growth when it falls below a threshold. On
increasing pathogen growth rate, the immune mediators stay elevated and persistent non-
infectious inflammation is observed. The concentrations of pathogen, early phagocytic cells,
cytokines, nitric oxide and tissue dysfunction in both these scenarios is shown in Figure 2.15
and Figure 2.16.
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2.3.3 Connections
The reduced models and the detailed models exhibit qualitatively similar behavior in terms
of the scenarios they are able to reproduce and the parameter changes that take the system
from one scenario to the other. Several features are conserved between the models and later
in this section, some simulations and bifurcation plots from the detailed models are compared
to those from the 3-d model.
The interactions of the 3-d model are obtained from reducing the global detailed model.
In the global model, an invading pathogen (initial condition of the variable P ) triggers an
immune response by activating the resting phagocytic cells (resting macrophages Mr) get
converted to activated forms. (activated macrophagesMa). These cells directly and through
cytotoxic products (NO and O2) clear the pathogen. This results in the production of toxic
pathogen products (endotoxin Pe) which further trigger immune response. This initial loop
is simplified in the 3-d model by assuming a growing pathogen p triggering a reaction from
a single immune mediator m which can directly clear pathogen.
In the global model, the early immune responses trigger further inflammatory products
such as the cytokines TNF-α and IL-6 and compensatory anti-inflammatory cytokines TGF-
β. Further downstream, the coagulation cascade (tissue factor Tf , thrombin Th and activated
protein-C Pc). These mechanisms along with increasing tissue dysfunction (D) and decreas-
ing blood pressure (B) further enhance inflammation. For instance, macrophages increase
rate of production TNF-α (at rate ktnfma) which in turn increase tissue factor (ktftnf ) which
increases thrombin (ktfth) and that increases IL-6 (k6th) which finally increases the activa-
tion rate of macrophages (km6). Such loops are simplified in the 3-d model through a single
late inflammatory mediator, l that enhances the early mediator m. The saturating effects
of anti-inflammatory agents such as TGF-β and activated protein-C are simulated through
saturating functions in the equations of both m and l.
All the scenarios that are possible in the 3-d model can be generated in the global model.
The variables in the larger model include more than one primary mediator (macrophages and
neutrophils), several secondary mediators and then another wave of pro- and anti inflamma-
tory mediators. So, scenarios not seen in the reduced model such as fixed points somewhere
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between clearly immuno-suppressed and clearly persistent infectious inflammation are also
possible in the global model. But going from one scenario to the other follows more or
less the same pattern in both models. The scenarios of persistent inflammation (infectious
and non-infectious), recurrent infection, immune-suppression as seen in the global model are
shown in Figs. 2.15 - 2.19. The structure of the phase space of the global model is clearly
complicated and is beyond the scope of detailed analysis. The persistent inflammation out-
comes are obtained by decreasing pathogen susceptibility (decreasing parameters kpm, kpno
and kp02) and the immuno-deficient outcomes are obtained by decreasing early immune re-
sponse to pathogen and pathogen products (decreasing parameters kmp, knp and ktfpe). The
bifurcation diagrams of the global model reveal the structure of fixed points which is very
similar or in some cases identical to that of the 3-d model (Figs. 2.21, 2.20).
The strength of the late inflammatory response in the 3-d model is crucial in determining
the predisposition of a system to persistent inflammation. More than one variable could
qualify as the strength of “late response” in the detailed model. Several parameters such as
k6m which governs the stimulation of IL-6 by macrophages or kdcp which governs the damage
caused by TNF-α can be changed and these result in qualitatively similar behavior as seen
in the reduced models: stable oscillations representing recurrent infection are followed by
unstable oscillations representing healthy behavior followed by the creation of a persistent
inflammation fixed point. In particular, the bifurcation plot of the parameter kdth, which
governs the strength at which thrombin stimulates damage, is shown in Figure 2.21. It can
be seen that it is very similar to Figure 2.10 which shows the variation of the strength of the
late inflammatory mediator in the reduced model.
The global model also shows similar dynamics when the early immune response is
changed. The parameter kmp which governs the pathogen stimulation of macrophages is
varied as shown in Figure 2.20. Low stimulation causes recurrent infection and higher stim-
ulation causes healthy behavior. However just as it is observed in the reduced model (Figure
2.9), even on increasing kmp to very large values, the possibility of a healthy outcome is never
lost.
Detailed results based on both the global and reduced models have been discussed. It
is expected that the validity of the above conclusions not change with small changes in the
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functional form of the model. This concept is formally referred to as “structural stability”.
The general idea is that similar dynamics (topological equivalence) is shown by a system
even when the functional forms (or parameters) of the system are slightly varied (Kuznetsov,
1998). Necessary and sufficient conditions for structural stability in 2 dimensions (Peixoto,
1962; Arrowsmith & Place, 1990) can be stated as follows. 1) All fixed points are hyperbolic
2) All closed orbits are hyperbolic 3) There are no orbits connecting saddles. While the local
conditions (1) and (2) are satisfied in the 2-d model (2.4-2.3), the global condition (3) is
not satisfied. So though local structural stability can be proved in compact sets in the 2-d
model, it is not globally structurally stable.
In dimensions higher than 2 only “sufficient” conditions for structural stability can be
stated (Garcia & Teixeira, 2004). These are the Morse-Smale conditions and the structural
stability of the system away from local bifurcations (such as the Hopf and saddle-node bifur-
cations seen in the 3-d (2.8-2.10) and global models (2.40)) can also be proved (Afrajmovich
et al., 1988). These conditions are stated as follows. 1) There is only a finite number of
fixed points and periodic trajectories 2) All such fixed points and periodic trajectories are
hyperbolic 3) the stable and unstable manifolds intersect transversally. While conditions (1)
and (2) are satisfied in the models (2.8-2.10) and (2.40), condition (3) can be proved formally
only on further analysis of the stable and unstable manifolds (Day, 2004).
It is noted however, that the specific nature of the interactions in the 3-d model are not
essential for the qualitative dynamics found. There is some flexibility in the functional form
chosen. As an example, the factor 1−m in (2.9) may be replaced by 1/(1 +m) or the form
of the coupling function (2.11) can be changed without affecting the conclusions. In this
study, we have shown qualitatively similar dynamics in the global and reduced models only
through simulations and similarities in bifurcation diagrams.
2.4 LIMITATIONS OF THE MODELS
The modeling approach has proven very useful in understanding the dynamics of acute
inflammation. However, there are certain limitations as discussed below.
In the models above, trajectories that were unstable spirals were interpreted as healthy
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Figure 2.15: Simulation of a healthy inflammatory response to Gram-negative bacterial infec-
tion: The system is infected by a low dose of Gram-negative bacteria (e.g. E. coli, Panel A),
which leads to activation of macrophages (Panel B). The macrophages elaborate cytokines
(Panel C), including rapidly produced pro-inflammatory cytokines (CP, e.g. TNF-α), more
slowly produced pro-inflammatory cytokines (CPL, e.g. IL-6), and anti-inflammatory cy-
tokines (Ca, e.g. TGF-β1). Tissue damage/dysfunction (Panel D) rises due to the actions
of pro-inflammatory cytokines and effectors, but then decreases due to the actions of anti-
inflammatory cytokines. Thus, homeostasis is restored after pathogens are cleared.
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Figure 2.16: Simulation of persistent non-infectious inflammation: The system is infected
by a high dose of Gram-negative bacteria (e.g. E. coli, Panel A), which leads to activa-
tion of macrophages (Panel B). The macrophages elaborate cytokines (Panel C), including
rapidly produced pro-inflammatory cytokines (CP, e.g. TNFα), more slowly produced pro-
inflammatory cytokines (CPL, e.g. IL-6), and anti-inflammatory cytokines (Ca, e.g. TGF-
β1). Tissue damage/dysfunction (Panel D) rises due to the actions of pro-inflammatory
cytokines and effectors, and unlike the case in Fig. 2.15 is not reduced. Thus, the inflam-
matory response is sustained, with ensuing adverse outcome.
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Figure 2.17: Simulation of persistent infectious inflammation: The system is infected by a
very fast growing Gram-negative bacteria (e.g. E. coli, Panel A), Macrophages are shown
in Panel B, Cytokines in Panel C and Tissue damage/dysfunction in Panel D. Unlike the
case in Fig. 2.15 inflammatory mediators are not reduced as the response elaborates. Also,
unlike Fig. 2.16, the pathogen load also does not reduce and active infection persists despite
severe inflammation. The inflammatory response and infection are sustained, with ensuing
adverse outcome.
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Figure 2.18: Simulation of recurrent infection: A virtual patient is infected by a slow growth
rate Gram-negative bacteria, (Panel B). Macrophages are shown in Panel B, Cytokines in
Panel C and Tissue damage/dysfunction in Panel D. The low growth rate infection does not
elicit a strong response and persistent low-grade inflammation exists.
45
0 100 200 300 400
Time
0
0.002
0.004
0.006
0.008
T N
F ,
 I L
- 6
 
0
2
4
6
8
10
P a
t h
o g
e n
0 100 200 300 400
Time
0
0.005
0.01
0.015
0.02
0.025
0.03
T i
s s
u e
 D
y s
f u
n c
t i o
n
0
5e-06
1e-05
1.5e-05
2e-05
M
a c
r o
p h
a g
e s
A B
C D
IL-6
TNF
Figure 2.19: Simulation of severe immuno-deficiency: The system is infected by a moderate
dose of Gram-negative bacteria (Panel A). The immune response is very weak (Panels B,C
and D) and this results in unchecked pathogen growth and background levels of inflammatory
mediators. An adverse outcome is expected to ensue in the organism due to large amounts
of pathogen, even though the damage term of the model in Panel D remains low.
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Figure 2.20: The bifurcation plot varying the strength of macrophage and neutrophil response
to pathogen and tissue-factor response to endotoxin. Even on increasing the response to very
high values, healthy oscillations are always a possible outcome.
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Figure 2.21: The bifurcation plot varying the strength of thrombin stimulation of damage is
very similar to that of varying the strength of the late inflammatory response in the reduced
model.
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outcomes. In general, these trajectories do take the pathogen values very close to 0 very
soon, and can be interpreted as healthy outcomes. However, the trajectories of some initial
conditions might wind longer around the fixed point before reaching p = 0. Such trajectories
cannot be immediately interpreted as healthy behavior and might be considered closer to
recurrent infection behavior.
Another draw-back is that though the outcomes of the reduced and global models have
been correlated to clinical conditions, strict correspondence is difficult to establish. The
persistent inflammation fixed point is interpreted as being in the “shock” state and leading
to death, though the exact pathway to death is not clearly modeled.
Some important aspects of the immune response have also been ignored in the models
above. For instance, the role of anti-inflammatory mediators could be more clearly examined
by explicitly including such a variable in a reduced model. Elements of adaptive immunity
may also be added to the global model to understand its systemic effects. Effort is ongoing
in that direction (Day, 2004).
The effects of fluctuations at low numbers have been ignored by the above models and
arbitrary thresholds have been used to ensure elimination of pathogen. Chapter 4 discusses
a more fundamental approach to deal with this problem.
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2.5 APPENDIX TO THE 2-D MODEL
The most general 2-dimensional model with positive coefficients is described and the stability
properties of its fixed points are analyzed.
dp
dt
= kpp− kpmmp− ksp2 (2.18)
dm
dt
= kmpmp− kmm+ kfm2. (2.19)
The nullclines of the most general model are
0 = p[p− kp − kpmm
ks
] (2.20)
0 = m[p− km − kfm
kmp
] (2.21)
and the fixed points (FP) are:
FP 1: p = 0, m = 0 (exists always)
FP 2: p = (km − kfm∗)/kpm, m∗ = (kmks − kmpkp)/(kfks − kpmkmp) (exists always; when
kf = 0 is modified to p = km/kmp,m = (kpkmp − kmks)/(kpmkpm); when ks = 0 is modified
to p = (km − kfkpkpm )/kmp,m = kp/kpm; and is p = km/kmp,m = kp/kpm when both kf and ks
are 0)
FP 3: p = 0, m = km/kf (does not exist if kf = 0)
FP 4: p = kp/ks, m = 0 (does not exist if ks = 0).
The Jacobian of (2.18,2.19) can be written out to determine the stability of the fixed
points listed above.
 kp − kpmm− 2ksp −kpmp
kmpm kmpp+ 2kfm− km
 (2.22)
Plugging p = 0,m = 0 in the Jacobian, the eigen-values of FP 1 can be obtained as kp,−km
which is always a saddle. FP 3 has eigen-values kp − ((kpmkm)/kf ), km. So FP 3 is a saddle
if kf < (kpmkm)/kp and unstable otherwise. FP 4 has eigen-values −2kp, ((kmpkp)/ks)− km.
So FP 4 is stable if kmp/km < ks/kp and a saddle otherwise.
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For FP 2, the case where ks = 0 is examined first for simplicity and then generalized to
when ks 6= 0. When ks = 0, in order that FP 3 lie in the positive quadrant, kf < kpmkm/kp.
FP 3 can be plugged into the Jacobian (2.22) and a characteristic equation for its eigenvalues
can be obtained as follows: λ2 − (kfkp/kpm)λ + (kpkm − (k2pkf )/kpm) = 0. To ensure an
unstable spiral, the real part of λ < 0 or kf < 0; to ensure that FP 2 is a spiral, λ should
be a complex number. The condition kf < kpmkm/kp is a stronger one and we retain that
for the behavior of interest i.e., unstable spiral in the positive quadrant. When there is a
positive saturation term for pathogen growth, ks > 0, the additional conditions kf > ks is
specified for the negative spiral to exist.
In the case where the term θp2 is added to the p equation rather than subtracting the
logistic term ksp
2, FP 2 is an unstable spiral unless kf < θ i.e. kf is a smaller negative
number than θ.
(kf , ks (ks being positive or negative) determine the slopes of the nullclines that intersect
to form FP 2. The stability of FP 2 depends on the angle at which the nullclines intersect
and hence on kf and ks. FP 2 is an unstable spiral as long as kf > ks and stable when
kf < ks and exhibits centers when kf = ks).
2.6 APPENDIX TO THE 3-D MODEL
In this section, a detailed phase-plane analysis of the 3 dimensional model of acute inflam-
mation is carried out.
2.6.1 Eigenvalues of Fixed Points
The Jacobian matrix of the model (2.8) - (2.10) is

kp(1− 2p)− kpmm −kpmp 0
kmpm(1−m) (kmpp+ l)(1− 2m)− 1 m(1−m)
0 klm
w
sech2(m−θ
w
) −kl
 (2.23)
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2.6.1.1 FP 1 For FP1: p = 0,m = 0, l = klm
kl
(1 + tanh(θ/w))(≡ l0), the Jacobian is

kp 0 0
0 l0 − 1 0
0 klm
w
sech2 θ
w
−kl
 . (2.24)
This matrix is lower-triangular and the eigenvalues are kp, l
0 − 1,−kl. The fixed point is
never stable as one of the eigenvalues kp is always positive.
2.6.1.2 FP 2 For FP2: p = 1,m = 0, l = l0, the Jacobian is

−kp −kpm 0
0 (kmp + l
0)− 1 0
0 klm
w
sech2 θ
w
−kl
 . (2.25)
The characteristic polynomial for the eigenvalue λ is
(−kp − λ)(−kl − λ)(kmp + l0 − 1− λ) = 0
with roots: λ = −kp, λ = −kl and λ = kmp + l0 − 1. Thus the condition for stability of
FP2 is kmp < 1− l0 or kmp < 1− klmkl (1− tanh(θ/w)). The other two eigenvalues are always
negative.
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2.6.1.3 FP 3 FP3 is the solution of the following equations,
p = 1− am (2.26)
m = 1− 1
kmpp+ l
(2.27)
l = bf(m) (2.28)
This may be reduced to a single transcendental equation for m:
m = 1−
(
1
kmp
(
1
1− am
)
+ bf(m)
)
. (2.29)
All the parameter combinations affect the position and eigenvalues of FP 3. Parameter
choices for which p or m of FP 3 is negative are unphysical. FP 3 could also have real or
complex eigenvalues. FP 3 has complex eigenvalues and can support oscillatory behavior
when (2.16) intersects (2.17) such that m of FP 3 is less than m of FP 4 (Fig. 2.7). FP 3 can
undergo Hopf bifurcations in this part of the phase-space - the subcritical Hopf bifurcations
on varying the three parameter combinations are shown in Figs. 2.8, 2.9, and 2.10.
A supercritical Hopf bifurcation occurs when we change the coupling curve (2.11) so
that θ is small (low threshold for activation) and w is large (shallow coupling curve). In this
case, for increasing b while keeping a and kmp fixed at moderate values, a state of persistent
non-infectious inflammation will follow recurrent infection and a small zone of stable limit
cycles. (Varying the other parameters, for small θ and large w, does not result in Hopf
bifurcations). In the case of small w (sharp coupling curve) and small θ (low threshold of
activation), it is possible that more than one fixed point satisfies the conditions for FP 3.
In this case, curve (2.17) intersects line (2.16) twice before dipping below zero. On varying
the parameter combinations, recurrent infection is bistable with persistent inflammation
and healthy behavior is never supported. These cases are discussed in greater detail in
Appendix 2.6.2.1. In our numerical examples, we have considered moderate w and large θ,
which result in subcritical Hopf bifurcations.
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2.6.1.4 FP 4 and FP 5 These fixed points are the solutions of the following equations,
p = 0 (2.30)
m = 1− ( 1
kmpkpmp+ l
) (2.31)
l =
klm
kl
f(m) (2.32)
This may be reduced to one transcendental equation
bf(m) =
1
1−m (2.33)
Equation (2.33) may have 0, 1 or 2 solutions depending on the parameters. Approximate
solutions can be found for (2.33) by substituting a piece-wise linear function such as f(m) =
0,m < θ−w; f(m) = 1+ (m−θ)
w
, θ−w < m < θ+w; f(m) = 2,m > θ+w. Using the above
approximate function and assuming that FP 4 and 5 occur in region θ−w < m < θ+w, we
arrive at the following expressions for FP 4 and 5.
p = 0 (2.34)
m =
q ∓
√
q2 − 4w
b
2
(2.35)
l = bf(m) (2.36)
where q ≡ 1− θ + w.
This gives b > 4w/q2 as a lower limit on b for the existence of FP 4 and 5. When there
are two solutions, they are formed through a saddle-node bifurcation as shown in Fig. 2.10.
FP 4 is a saddle point and FP 5 is a stable node.
The eigenvalues of FP 4 and 5 can be found by substituting the solutions m = m0 of
(2.33) into the Jacobian (2.23). One of the eigenvalues is λ1 = kp − kpmm0 and the other
two are functions of the parameters kl, klm, θ and w. We note that kmp does not appear in
the expressions for the position or eigenvalues of FP 4 and 5.
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2.6.2 Regimes for healthy response
Trajectories can be interpreted as healthy when FP 3 supports unstable oscillations as an
unstable spiral or as a stable spiral surrounded by an unstable limit cycle. The unstable limit
cycle is lost when it undergoes a non-generic homoclinic bifurcation when it collides with
FP 1. The regimes of the various parameters (for fixed θ and w) which maintain healthy
behavior are discussed below.
For healthy behavior, a should be large enough so that FP 3 is to the left of FP 5 in
Fig. 2.7 or (1/a) < (q −
√
q2 − 4w/b)/2. Increasing kmp even over a large range, does not
make FP 3 unphysical, nor does FP 3 lose its complex eigenvalues - thus even for very large
kmp, healthy oscillations are supported. The upper limit for a and the lower limit for kmp
to maintain healthy oscillations are difficult to find in closed form as these variations result
in the radius of the limit cycle increasing and oscillations being lost through a non-generic
homoclinic bifurcation.
The strength of the late immune response b should not be too high or too low. If b is
too high, then FP 3 has p < 0 and hence healthy behavior cannot be supported. In order
for the late immune response to not be too high, we require that p of condition (2.17) be
positive so that FP 3 is not unphysical. Applying this to (2.17) gives the condition
b <
1
1− tanh(θ/w) . (2.37)
If b is too low, FP 4 and 5 are not yet formed and (2.17) is well above p = 0 so FP 3 remains
the global attractor and is a stable spiral. To avoid too low of a response, we would like FP
4 and 5 to exist so that unstable oscillations from FP 3 are eventually attracted to FP 5.
Thus the condition for existence for FP 4 and 5, as calculated above in 2.6.1.4, is
b >
4w
(1− θ + w)2 . (2.38)
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2.6.2.1 Effect of varying the coupling curve The shape of the coupling curve (2.11)
(i.e. parameters θ and w) can alter the results. We used θ = 1 and w = 0.5 in our analysis.
Parameter θ sets the threshold where l is activated bym and parameter w gives the steepness
of recruitment.
From numerical simulations when θ = 1, we find that when w is too small, FP 3 never
undergoes a Hopf bifurcation, and as klm/kl is increased, recurrent infection and persistent
inflammation are bistable (For example, w = 0.005 with ’healthy’ parameter set in Fig. 2.2).
As discussed in Appendix 2.6.1.3, small w could result in a shallow enough curve (2.17) that
intersects line (2.16) more than once. The two fixed points replacing FP 3 arise in a saddle-
node bifurcation. The stable node is bistable with FP 5 implying that recurrent infection
is bistable with persistent non-infectious inflammation. When w is too large (w = 1), FP 3
is a stable spiral that becomes unphysical as klm/kl increases. Thus the system supports
recurrent infection followed by persistent inflammation and healthy behavior does not exist.
In summary, for w too small or large the subcritical Hopf bifurcation of FP 3 (and hence
healthy behavior) does not occur for any of the parameter combinations.
On keeping w fixed at 0.5 and varying θ, when θ is small (θ = 0.1), FP 3 undergoes a su-
percritical Hopf bifurcation as b is varied but this cannot be generically interpreted as healthy
behavior as oscillations about a stable limit cycle may not always take p below threshold.
As θ is increased, subcritical Hopf bifurcations are possible. The range of parameter b, given
by (2.37) and (2.38), where oscillatory behavior is observed also increases as θ is increased.
Thus, large θ and moderate w would maximize the region for healthy response. Figures 2.13
and 2.14 show bifurcation plots when these parameters are varied together.
In the above analysis, we have looked at varying parameter combinations rather than
individual parameters for conciseness of the discussion. Varying the parameters such as
kp and kpm individually does not change the bifurcation diagrams qualitatively and our
interpretations of the effect of pathogen susceptibility remain unchanged. Similarly, varying
klm and kl individually does not change our conclusions about the strength of late response.
The phase-space analyzed is restricted between 0 < m < 1 since condition (2.17) prevents
m from increasing beyond one. Using any other function such as 1/(1 +m) to saturate m
can change the upper bound of m but the same behavior is retained.
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2.7 APPENDIX TO THE GLOBAL MODEL
2.7.1 Table of mediators modeled
(Courtesy of Dr. G. Clermont)
Model component Symbol Comment
Pathogen P Generic Gram negative pathogen
Lipopolysaccharide Pe Immunostimulant derived from Gram-negative bacteria
Resting macrophage Mr Circulating monocyte or local macrophages that act
as a cellular pool for activated macrophages.
The total count of resting macrophages can
increase in proportion to the total inflammatory activity
Activated macrophage Ma Activation triggered by LPS, TNF, IL-6, tissue trauma
and tissue dysfunction. Activation is down regulated by
anti-inflammatory cytokines
Activated neutrophil N Activation triggered by LPS, TNF, IL-6
and tissue dysfunction
Nitric Oxide NOD Combines activities of constitutive & inducible
Synthase (NOS) NOS. Normally participates in blood pressure homeostasis
Increased by LPS, TNF in N & Ma
Decreased by anti-inflammatory cytokines
Circulating NO2/NO3 NO Measures correlating with cumulative NOS activity
Tissue necrosis factor Cp Major early pro-inflammatory cytokine secreted mainly
by activated Ma, but also by N
IL-6 IL6 A pro-inflammatory cytokine with additional
anti-inflammatory effects
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Generic anti- Ca, Cr Ca represents the combined long-lived
inflammatory anti-inflammatory activity of IL-10, steroids, TGF-β
soluble receptors to pro-inflammatory cytokines & intra-
cellular products with anti-inflammatory activity
such as heat-shock molecules. As a group, their
anti-inflammatory activity is triggered by TNF,
IL-6, and nitric oxide
Activated Protein C PC An anti-thrombotic and anti-inflammatory agent
Tissue factor Tf Promoted by pro-inflammation, increases dysfunction
Thrombin TH Represents global pro-coagulant/anti-coagulant balance
also participate in blood pressure and dysfunction
Blood pressure B At homeostasis depends mainly on NO. The B eqn. has
a “restoring” term for autonomic autoregulation
Tissue damage D Caused by hypotension, the action of pro-inflamm.
cytokines, tissue microthrombosis. NO is tissue-protective
and there is a slow natural repair process
2.7.2 Estimated values of parameters
The 72 parameters that determine reaction rates are given below.
kpg 0.1 kps 0.001 P0 0.0001 kpm 0.1 kpNO 0.5 kp02 1.0 kpe 0.2 kmp 0.5
kmpe 0.02 kmd 0.04 kmm 0.1 km6 0.8 kmr 0.05 Sm 0.1 kma 0.2 knp 0.2
knpe 1.5 kncp 0.4 kn6 2.0 knd 0.2 kns 0.1 knNO 1.0 knO2 6.0 kn 0.04
Sn 0.001 kNOn 0.25 kNOm 0.2 kNO6 0.05 kNOD 0.1 kNO 0.1 kO2n 0.2 kO2m 0.1
kO26 0.1 kO2np 0.01 kO2 0.5 kcpn 0.5 kcpmr 0.0005 kcpm 0.5 kcpcp 0.71 kcp 2.5
k6m 0.4 k6th 0.4 k6cp 1.0 k6 0.1 kcan 0.1 kcam 0.04 kcacp 0.1 kca6 0.04
kcaNO 0.1 kcaO2 0.1 kcar 0.5 kca 0.02 ktfpe 0.01 ktfcp 0.1 ktf6 0.1 ktf 0.1
kthl 0.05 kthn 0.004 kth 0.1 kpcth 0.1 kpc 0.1 kB 0.2 kbno 0.02 kbcp 0.02
kbth 0.2 kdb 0.1 kdcp 0.01 kdO2 0.02 kdNO 0.01 kdeq 0.1 kdth 0.05 kd 0.03
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The following 20 parameters are used only in the case of specific interventions and are
set to 0 in the base-line case.
Spe rate kab tab resist
kape tape katnf tiatnf tfatnf
dur Spc tpcon tpcoff kBh
tBon tBoff kds tdon tdoff
The various thresholds of activation are as follows.
θ 1.0 θcpca 1.0 θca 10.0 θ2 10.0 θcp6 1.0 1 θcp 1.0 θ6 1.0
2.7.3 The global model
dP
τdt
= kpgP (1− kpsP )H(P − P0)− kpmMa + kpNONO + kpO2O2 + kabH(t/τ − tab) (2.39)
dPe
τdt
= (kpmMa + kpNONO + kpO2O2 + kabH(t/τ − tab))P − kpePe
dMr
τdt
= −(kmpP + kmpePe + kmdD)(Sm + f2(Cp, θcp) + km6f2(IL6, θ6))fCa(Ca, θca)Ma
+ kmmf(Cp +NO + Pe, θ)− kmrMr + Sm
dMa
τdt
= (kmpP + kmpePe + kmdD)(f2(Cp, θcp) + km6f2(IL6, θ6))fca(Ca, θca)Mr − kmaMa
dN
τdt
= (knpf(P, θ2) + knpef(Pe, θ2) + kncpf(Cp, θcp) + kn6f(IL6, θ6) + kndf(D, θ2))N(1− knsN)
− (knNONO + knO2O2)N − kn(fs(Cp, θcp) + fs(IL6, θ6))N + Sn
dNOd
τdt
= (kNONN + kNOMMa)fca(Ca, θca)f(Cp, θcp) + kNO6f(IL6, θ6))− kNOdNOd
dNO
τdt
= kNO(NOd −NO)
dO2
τdt
= ((kO2nN + kO2mMa)(f(Cp, θcp) + k026f(IL6, θ6)) + kO2npNf(P, θ))fca(Ca, θca)− kO2O2
dCp
τdt
= (kcpnN + kcpmrMr + kcpmMa)fca(Ca, θcpca)(1 + kcpcpf(Cp, θcp))
− kcpCp − katnfS(tatnf , tatnf+dur, τ)Cp
dIL6
τdt
= k6mMa(1 + k6thf(Th, θ))fca(Ca, θ2)− k6IL6
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dCr
τdt
= (kcanN + kcamMa)(kcacpf(Cp, θcp) + kca6f(IL6, θ6)
+ kcaNOf(NO, θ) + kcaO2f(O2, θ))− kcrcr
dCa
τdt
= Cr − kcaCa
dTf
τdt
= (ktfpePe + ktfcpCp + ktf6IL6)fs(Pc, θ)− ktfTf
dTh
τdt
= (kthlTf + kthnTh)− kthTh
dPc
τdt
= kpcthTh − kpcPc + SpcS(tcon, tcoff , τ)
dB
τdt
= (kB(1−B)− (kbNPNOfs(O2, θ) + kbcpCp + kbthTh)B − (B − kB)S(tBon, tBoff , τ)
dD
τdt
= (kdb(1−B) + kdcpCp + kdO2O2 + kdNONOfs(NO, θ2) + kdeqO2 exp(−10(NO −O2)2)
+ kdthTh − kdD + kdsS(tdon, tdoff , τ) (2.40)
where, the functions are as follows:
f(v, θ) = θv/(v + θ)
f2(v, θ) = θv
2/(v2 + θ)
fs(v, θ) = θ/(v + θ)
fca(v, θ) = θ/(v
2 + θ)
S(ti, tf , τ) = H(t/τ − ti)−H(t/τ − tf )
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3.0 APPLICATIONS OF A GLOBAL MODEL OF ACUTE
INFLAMMATION - (I) ANTHRAX AND (II) CLINICAL TRIALS
In Section 2.3, a model of acute inflammation that incorporated some of its key features was
described. Some preliminary results from it were also listed. In this chapter, some more
detailed results from model simulations are discussed.
In the first section, the results from a modified version of the global model are discussed.
The properties of the invading pathogen are changed to represent those of the anthrax
bacterium bacillus anthracis. The typical time course of inhalational anthrax infection is re-
produced. Some predictions about treatment strategies are suggested (Kumar et al., 2004a).
In the second section, an attempt is made to understand the effects of genetic diversity in
a population by varying select parameters in the model (2.40). Based on such models, clinical
trials to test the effectiveness of therapies could be more effectively designed (Clermont et al.,
2004).
3.1 ANTHRAX
The history of human infection with anthrax is centuries old. More recently much has been
learned about the molecular pathology of this bacterium. These developments have been
spurred on by the potential and, more recently, actual use of this bacterium as a weapon of
bioterror (Dixon et al., 2004). Anthrax modulates the acute inflammatory response of the
host, and systemic anthrax infection is thought to result in a condition similar to sepsis and
septic shock.
Three basic routes of infection are known for anthrax: cutaneous, gastrointestinal, and in-
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halational. Cutaneous anthrax is introduced into the skin through cuts or abrasions, presents
as relatively nondescript skin lesions that turn a black-purplish color due to local inflamma-
tion, and resolves either on its own or with a 60-day course of antibiotics. Gastrointestinal
anthrax is caused by ingestion of meat contaminated with anthrax spores, which enter the
body through some break in the mucosal lining, causing fever, abdominal pain, diarrhea,
constipation, or vomiting, and can result in death from perforation of the intestine or from
sepsis. The third, and most lethal, form of anthrax infection is inhalational. The initial
symptoms are “flu-like”, caused by an exuberant inflammatory response: fever, coughing,
myalgia, and malaise. The disease becomes much more severe after 1-3 days, manifesting
with dyspnea, strident cough, chills, and eventually death. Though natural inhalational an-
thrax infection is considered rare, it is the most threatening form of anthrax infection from
the point of view of bioterrorism (Shahfazand et al., 1999).
Current therapeutic strategies for inhalational anthrax are no less complex than those
for sepsis and are limited in their effectiveness (Hotchkiss & Karl, 2003).
3.1.1 Pathogenesis of anthrax infection
The pathogenesis of anthrax is more involved than that of a standard gram negative bacterial
infection as discussed in Chapter 1. However, death from inhalational anthrax is thought to
occur through the common process of systemic inflammation and bacteremia (Shahfazand
et al., 1999; Abramova et al., 1993).
Anthrax infection is initiated by inhalation of aerosolized anthrax spores, which are inter-
nalized by monocytes/macrophages/dendritic cells. The spores can incubate for a period of
over 40 days (modal incubation period 0-10 days) during which time monocytes and imma-
ture dendritic cells may circulate and therefore spread latent anthrax infection throughout
the body. Given the appropriate temperature and/or CO2 levels (Dai & Koehler, 1997),
the spores germinate. The major toxins of B. anthracis are protective antigen, lethal factor,
and edema factor. These three exotoxins are synthesized and each form heterodimers that
result in bioactive molecules: edema toxin is a heterodimer of protective antigen and edema
factor, and lethal toxin consists of protective antigen bound to lethal factor (Shahfazand
61
et al., 1999; Dixon et al., 2004).
Edema factor is a calmodulin-dependent adenylate cyclase, which causes elevations of the
intra-cellular second messenger cyclic adenosine mono phosphate (cAMP) (O’Brien et al.,
1985). Edema toxin attracts neutrophils to the site of infection, but suppresses the capac-
ity of these cells to phagocytose bacteria and to produce super-oxide in response to this
phagocytosis.
Lethal factor, a zinc metalloprotease, inactivates members of the mitogen-activated pro-
tein kinase family of signaling molecules, known to be involved in the responses to stress
and inflammation (Bonventre, 2003). In vitro evidence shows that lethal toxin in small
doses stimulates macrophages to produce IL-1β and TNF-α and in large doses causes lysis
of macrophages (Friedlander, 1986). In the process of macrophage death, it has been hy-
pothesized that there is an apparent rapid and overwhelming release of pro-inflammatory
cytokines which is thought to result in the ’sudden death’ seen in inhalational anthrax. Thus
lethal toxin through a macrophage dependent process is thought to be the principal cause
of death in anthrax infection (Hanna et al., 1993).
Protective antigen plays the important role of allowing intra-cellular entry of the other
two factors by binding to them. Even though it has no direct toxic effects, strains of bacteria
deficient in protective antigen production are far less virulent than the wild type bacterium
(Pezard et al., 1995; Brossier et al., 2000).
However, there has been evidence recently that suggests that mortality due to anthrax
is due to non-inflammatory mechanisms and due to hypoxia-induced liver failure where an
Fas-L dependent process has been implicated (Prince, 2003). Mice injected with anthrax
lethal toxin intra peritoneally have revealed no evidence of TNF production or symptoms
of systemic inflammation. Tissue hypoxia, liver necrosis and pleural edema and an initial
spike of IL-1β concomitant with macrophage lysis were observed (Moayeri et al., 2003).
However, these observations were based on i.p. injections of anthrax toxins and pathogenesis
of such a gastro-intestinal disease might well be different from that of inhalational anthrax
infection(Abramova et al., 1993).
The virulence of anthrax is enhanced by yet another factor. The vegetative bacteria is
enclosed in a anti-phagocytic poly-D-glutamic acid capsule. This makes the bacteria more
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difficult to phagocytose (Hanna et al., 1993). In fact, non-encapsulated versions of the strain
are attenuated enough that they are routinely used as vaccines in animals (Schneerson et al.,
2003).
3.1.2 Simulations from a model of anthrax infection
The equations ( 2.40) model the acute inflammatory response to a general gram negative
bacterium. This is modified to simulate the typical course of an anthrax infection by in-
troducing equations describing the specific properties of anthrax bacterium. Based on the
hypotheses of the pathogenesis, a variable for the sterile spore is introduced which gets in-
gested by patrolling resting macrophages. The macrophage is activated and the bacteria
start growing and these processes are modeled using the following equations.
dSPORE
τdt
= −kspSPORE ∗Mr (3.1)
dP
τdt
= kpgP (Mr +Ma − kpsP )H(P − P0) (3.2)
− (kpmMa + kpNONO +KpO2O2 + kabH(t− tab))P + kspSPOREMr(3.3)
dMa
τdt
= kmpP + kmdD)(f2(Cp, θcp) +Km6f2(IL6, θ6))
fca(Ca, θca)Mr − kmaMa +Kmlt(LTMr − L2TMa) + kmspSPOREMr
(3.4)
The growing bacteria releases the edema factor, lethal factor and protective antigen which
are modeled as follows.
dEF
τdt
= kefpP − kefEF
dLF
τdt
= klfpP − klfLF
dPAF
τdt
= kpafpP − kpafPAF
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Edema factor combines with protective antigen to form edema toxin and lethal factor simi-
larly forms lethal toxin as follows.
dET
τdt
= kepafEFPAF − ketET
dLT
τdt
= klpafLFPAF − kltLT
The effects of these toxins are modeled by modifying the previously existing equations.
Lethal toxin gets absorbed by resting macrophages and in large quantities causes its lysis
and massive release of TNF. This is reflected as follows in the equations for TNF.
dCp
τdt
= (kcpnN + kcpmrMr + kcpmMa)fca(Ca, θcpca)(1 + kcpcpf(Cp, θcp)) + kcpBOMB(kmltMaL
2
T )
− kcpCp − katnfS(tatnf , tatnf+dur, τ)Cp
Edema toxin increases concentration of neutrophils but decreases their capacity to produce
O2 and NO which are the chemicals that are actually involved in phagocytosis as shown
below.
dN
τdt
= (knetET + knpf(P, θ2) + kncpf(Cp, θcp) + kn6f(IL6, θ6) + kndf(D, θ2))N(1− knsN)
− (knnoNO + kNO2O2)n− kn(fS(Cp, θcp) + fs(IL6, θ6))N + Sn
dO2
τdt
= (
kO2nN
1 + ET
+ kO2mMa)(f(Cp, θcp) + k026f(il6, θ6))
+ kO2npnf(P, θ))fca(Ca, θca)− kO2O2)
The anthrax bacteria is more difficult to phagocytose than a gram-negative bacteria
because of its capsule. Thus, anthrax infection leads to shock and large bacterial counts sys-
temically. These changes to the model of gram-negative sepsis are summarized in Appendix
3.3. However, the model’s immune parameters that were fixed using the model (2.40) were
not modified.
Simulations from the modified model for anthrax infection are shown in Figure 3.1 and
can be compared with the sepsis simulations from a generic gram negative bacterium in
Figure 2.16. Anthrax-mediated tissue damage/dysfunction (representative of organ damage
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and, presumably, lethality) remains elevated for several hours. Bacteria remain uncleared
despite high levels of inflammation. (In order to offer an unbiased comparison between Gram-
negative infection and anthrax, the number as well as intrinsic growth and death parameters
of all bacteria are kept the same.) Thus severe septic shock is the outcome of infection with
anthrax bacterium at an inoculum that is non-lethal in the case of regular gram negative
bacteria.
3.1.3 Treatment and prevention strategies: Current status
Below some of the most frequently used treatment strategies against anthrax are examined.
Though several have been developed to deal with the epidemic in animals, vaccination data
from humans is understandably difficult to come by. Analyzing the results from mathematical
models like these provides clinicians with vital clues about administration of therapies.
One of the most common treatment methods for all infections, including anthrax, is
antibiotic administration. Antibiotics may work for cutaneous and gastro-intestinal anthrax.
However, it has been widely accepted that by the time the symptoms of inhalation anthrax
are patent, it is too late for anti-microbial therapy to be effectual (Shahfazand et al., 1999;
Dixon et al., 2004).
Various types of vaccines have been suggested to be used in animals and susceptible
human populations. “Live” vaccines are preparations made from naturally occurring atten-
uated bacteria or genetically modified versions which are less virulent. Injecting such vaccines
has been shown to effectively protect most animals from anthrax. However, inherent risks
of live bacterial injections are associated with these vaccines (Pezard et al., 1995).
Consequently, recent vaccines prepared for use in humans consist of “cell-free” filtrates
of the bacilli produced to increase the content of protective antigen (PA). The preparation
is then alum-precipitated to form the vaccine. There are few human studies of effectiveness
of such vaccines. In a single-blind placebo controlled study based on tannery workers, the
vaccine was found to be 92.5% effective in preventing anthrax. However, this included cases
of cutaneous anthrax and protection from the more serious inhalational anthrax could not
be assessed (Shahfazand et al., 1999).
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Thus effective and safe treatment and prevention strategies against inhalational anthrax
for susceptible human populations have not been determined and possible vaccine mecha-
nisms are investigated using the mathematical model.
3.1.4 Predictions from the model
Vaccination alone or in combination with antibiotic administration in the setting of an
anthrax infection has been simulated. An antibiotic was simulated as a chemical that would
kill live bacteria on contact. The vaccine was simulated by changing the parameters of
production of Protective Antigen (kpafp and kpaf ) to result in reduced amounts of available
Protective Antigen.
3.1.4.1 Vaccine against protective antigen alone may protect The model suggests
that effective vaccination against protective antigen results in tissue dysfunction that is
somewhat mitigated. This is not immediately interpretable as “dead” or “alive”. Though,
tissue dysfunction may be low, pathogen load remains high. This is because in the vaccinated
individual, protective antigen which is one of the key stimulators of the immune response, is
down-regulated. This could result in uncontrolled bacterial growth which could also lead to
death (Fig. 3.2).
The results that have been presented so far are of a single set of genetic parameters.
However, the outcome of an infection depends on several factors including the virulence of
invading pathogen, the size of the inoculum, and the patients coexisting conditions, age, and
gene polymorphisms (Hotchkiss & Karl, 2003). Varying the response of the macrophages
and neutrophils and early cytokines (kmp,knp,kcpn etc.), varies the effectiveness of the vaccine.
There are reasonable parameter values where the administration of protective antigen alone
is sufficient in restoring health (Fig. 3.4).
Based on model simulations, we can predict that the strategy of using anti-protective
vaccine alone can work for some individuals. When circulating neutrophils respond strongly
to the bacterial coat, it effectively counteracts the immune suppression caused by smaller
amounts of protective antigen. Increased production of NO aids in clearing bacteria and
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does not cause damage downstream. However, a strong macrophage response is confounding
as, based on our hypotheses, it could result in large amounts of circulating cytokines which
could lead to septic shock.
3.1.4.2 Combination therapy is the most ideal In Fig. 3.3, a simulation of the
predicted efficacy of pre-existing antibodies to protective antigen, in the presence or absence
of antibiotics is shown. This simulation is of one set of genetic parameters. In all cases, tissue
dysfunction is shown: rising tissue dysfunction is equated with death, while dysfunction that
returns to baseline is synonymous with survival. Anthrax infection by itself is simulated first
(Case 1; Fig. 3.3), and this would results in rising tissue dysfunction that is interpreted
as a negative outcome. The administration of antibiotics at t = 0 (Case 2; Fig. 3.3; an
unlikely scenario in an anthrax outbreak) resolves the infection and results in survival (falling
tissue dysfunction). The administration of antibiotics at t = 48 h (Case 3; Fig. 3.3; a
likely clinical scenario in an anthrax outbreak) results in death (rising tissue dysfunction)
essentially identical to that of Case 1, again in agreement with published results showing lack
of efficacy of late antibiotic administration in anthrax-infected mice (Kalns et al., 2002). The
presence of pre-existing circulating antibodies to protective antigen (Case 4; Fig. 3.3; the
anthrax vaccine case) results in reduced dysfunction as compared to Cases 1 or 3, but this
effect is not as dramatic as that observed in Case 2. This result is not immediately classifiable
as death as discussed above. However, if a patient has pre-existing circulating antibodies to
protective antigen and receives antibiotics at t = 48 h (Case 5; Fig. 3.3; a case representing
a vaccinated individual that is infected with anthrax), improvement is seen relative to Cases
1, 3, and 4 (but not Case 2). Thus, the model predicts that a combination of pre-existing
circulating antibodies to protective antigen and timely administration of antibiotics is the
vaccine is a realistic and effective strategy to deal with sepsis caused by anthrax. This
combination strategy is supported by experimental evidence in monkeys (Friedlander et al.,
1993).
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Figure 3.1: Modification of mathematical model of sepsis to account for anthrax-specific
effects: Comparison of the predicted effect on tissue damage/dysfunction of release of pro-
inflammatory cytokines in anthrax infection. We observe that despite an exuberant immune
response the bacterial load remains high. (The bacterial growth parameters are the same as
that of the gram-negative infection in Fig. 2.15)
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Figure 3.2: Vaccination against protective antigen leads to a decrease in the stimulation of
the immune response. The primary stimulants are now the bacterial coats and that is not
enough to clear bacteria. Therefore, though a down-regulated immune response leads to
lower damage, it also results in unbounded growth of bacteria
3.1.5 Discussion of the anthrax model
The approach to the problem of anthrax infection in the above argument, is to consider the
sequelae of inhalational anthrax exposure to be a specialized form of septic shock, and to
model mathematically the response to infection. The mathematical model of general acute
inflammatory response to gram negative bacteria (2.40) has been modified (3.3) to capture
features specific to anthrax infection, including the anti-phagocytic capsule, the synthesis
of edema toxin and lethal toxin from their components, chemoattraction of neutrophils and
subsequent suppression of their oxidative burst, and activation and subsequent destruction
of macrophages. Anthrax infection simulated with the above properties results in septic
shock with increased levels of cytokines, damage, decreased blood pressure and uncleared
bacterial load and is interpreted as death.
This model simulates the efficacy of antibiotic administration. As observed in animal
experiments, the model suggests that antibiotics administered early in the course of infection
are useful in clearing it and restoring homeostasis. Late administration of antibiotics is not
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Figure 3.3: Simulation of the efficacy of antibiotics and vaccination in inhalational anthrax:
Simulation of tissue damage/dysfunction under the various circumstances. Case 1, anthrax
infection, no antibiotics. Case 2, anthrax infection, antibiotic administration at t = 0. Case
3, anthrax infection, antibiotic administration at t = 48 h. Case 4, anthrax infection in the
setting of vaccination leading to pre-existing circulating antibodies to protective antigen.
Case 5, anthrax infection in the presence of vaccination and antibiotic administration at t
= 48 h
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Figure 3.4: Simulation of a set of parameters where vaccination alone is sufficient in curing
anthrax (kpafp is set = 0.001; its base value = 0.015) : Varying the parameters in the
model could resemble the inherent variations in a population. In the above simulation,
pathogen and vaccine properties are kept the same, but immune response parameters are
changed.knp = 4 ( 8 times base value), kNOn = 3 (6 times base value). Tissue dysfunction,
in the presence of anti-protective antigen vaccine, in the case of the base parameter values
is compared with the modified set.
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useful as it cannot alter the course of the infection (Kalns et al., 2002).
The effect of administering vaccines against protective antigen can also be tested in the
model. Experimental evidence about the efficacy of the vaccine in humans is sparse. We
suggest that vaccines on their own may be effective in clearing anthrax infection only in
some cases. Clearing protective antigen implies less of a stimulation to the immune system.
The model suggests that in a generic case, this could lead to a slow immune response which
grows with the bacteria and is ultimately inadequate in clearing it. However, individuals
with strong initial immune response to the bacterial coat and a muted late inflammatory
wave may be cured with vaccination alone.
The presence of protective antigen in the sequence of anthrax infection incites a strong
pro-inflammatory response in the body pre-disposing it to tissue damage and eventually sep-
tic shock. Therefore, clearing protective antigen using the vaccine has an anti-inflammatory
effect systemically. Given favorable circumstances, such as low virulence pathogen, well cal-
ibrated dosage of vaccine, administration of the vaccine alone could be enough to take the
system to health. However, in the scenario of depleted protective antigen, the main insti-
gator of the immune response is the growing pathogen alone and chances of an inadequate
immune response resulting in persistent infection and subsequent systemic inflammation are
high. Late antibiotics actually help in clearing pathogen and restoring the system to health.
Hence a combination therapy to down-regulate inflammation and to later clear bacteria is
likely to be successful for a large population.
3.2 CLINICAL TRIALS
In this section, the effectiveness of anti-TNF-α therapy in preventing sepsis in a population
is explored using the model (2.40). As discussed in Chapter 1, TNF-α is one of the key me-
diators in the acute inflammatory response and could play a major role in taking a system
to sepsis. Supported by data from animal experiments, it was believed that targeting to
down-regulate TNF-α in a septic patient was likely to alleviate the condition. Large ran-
domized clinical trials were conducted to test the hypothesis and the therapy failed to meet
the criteria for efficacy and was not approved (Reinhart & Karzai, 2001; Abraham et al.,
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1998).
In this analysis, we attempt to carry this out “in silico” to gain insight into the actual
effectiveness of the therapy. A protocol to best simulate the setting of a clinical trial is
designed. The model generates information on the possible biological markers, the genetic
profile of those benefitted and harmed by the therapy and the best timing and dosage for
its administration. The complete analysis is available in (Clermont et al., 2004).
The behavior of a system with varying parameters can be understood, in principle,
through a complete bifurcation analysis. But in the case of complex models, such a sys-
tematic analysis is likely to be very complicated. Instead, in the following study, only the
parameter regimes of interest are probed in parts (“randomization”) and some useful con-
clusions are drawn.
3.2.1 Design of the clinical trial
The clinical trial was designed to focus on the consequences of the administration of a
neutralizing antibody directed against the pro-inflammatory cytokine tumor necrosis factor
(anti-TNF) to sepsis patients (Reinhart & Karzai, 2001). This was simulated in the model
by adding a term to reduce the amount of TNF-α and the strength of this clearance is
controlled by the parameter katnf . This clearance is implemented by a Heaviside function
between times ti and tf (see model 2.40).
The effect of anti-TNF therapy is evaluated by administering to a genetically diverse
population, that is exposed to different insults. A population of 1000 virtual patients differing
in their initial bacterial load (p(0)), bacterial virulence (bacterial growth parameter kpg and
time of initiation of intervention (ti) are generated. Pathogen characteristics (growth rate
and initial load) were chosen to result in a survival of approximately 60%. The delay before
medical consultation, and thus time of initiation of treatment was variable and depended on
pathogen load and virulence (i.e. sicker cases would generally consult earlier).
To simulate genetic diversity of the study population, individual propensity of immune
cells to generate effector molecules (pro-inflammatory [TNF and IL-6], anti-inflammatory
[CA], and nitric oxide [NO] activity) was randomly varied between ±25% of baseline param-
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eters as dictated by literature data (Louis et al., 1998). Those variations were sufficient to
explain wide swings in individual serum levels of effectors.
To identify optimal dosing and duration of administration strategies, the virtual cohort
of 1000 patients were treated with nine different interventions of anti-TNF. The duration
of administration of anti-TNF (6h, 24h, or 48h) was varied (i.e. tf − ti). Comparatively,
the half-life of anti-TNF antibodies in naive patients is 40 to 50 hours (Fisher et al., 1993).
Three different “doses” of anti-TNF (2, 10, and 20 arbitrary units) were used (i.e. katnf ).
Depending on dose, TNF neutralization varied from 18.6% to 55.5% of total TNF produced
in controls. It is difficult to obtain a clear correlation with published reports as these do not
typically report areas under the curve, and do not always distinguish between biologically
active TNF, TNF bound by antibody and TNF bound by specific soluble receptors (Fisher
et al., 1993) .
3.2.2 Results and Discussion
The simulations clearly separate cases with favorable and unfavorable outcomes based on
global tissue dysfunction as shown in Figure 3.5. Overall mortality was 37.1% as determined
by tissue dysfunction at 168 hours divided by maximal tissue dysfunction at any point during
the first 168 hours. This variable is chosen as a proxy to unfavorable outcome because there
was a clear bimodal distribution of this variable after 72 to 96 hours. Therefore, the model
offered a natural separation of favorable and unfavorable outcomes.
There is a logical physiological correlate to this observation: after reaching a maximum,
tissue dysfunction tended to improve significantly and rapidly in some cases (survivors), or
remained elevated at a substantial fraction of maximum in all other cases (non-survivors).
Mortality was higher with high bacterial load, high virulence, and high TNF production
potential by effector cells.
Depending on dose and duration of treatment, survival ranged from 57.1% to 80.8%.
Higher doses of anti-TNF, although effective, also resulted in considerable harm to patients.
Trial optimization involves selecting a dosing strategy that optimizes outcome in a cohort
of patients, and then selecting patients that would benefit from treatment while avoiding
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treating patients for which treatment would have either no effect or cause harm.
A saturation of the effect of anti-TNF on peak and cumulative concentration of mediators
and tissue dysfunction was observed. Survival is highest when the lowest dose of anti-TNF
is administered for 48 hours, and worst when the highest dose is administered for 48 hours.
A surprising, yet key, finding is that anti-TNF treatment helps a significant percentage of
individuals, but also harms many. Thus, the beneficial effect of this therapy is reduced
considerably if administered in a randomized fashion.
It is also possible to identify subgroups with high propensity for being helped or harmed
by the proposed intervention, and identify early serum markers for each of those subgroups
(see (Clermont et al., 2004)).
The relationship between gene polymorphism and outcome of patients with sepsis has
been difficult to document (Louis et al., 1998). Although models such as the one presented
provide clear predictions, these are difficult to confirm in the absence of consistent clinical
and epidemiological studies.
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Figure 3.5: The clear separation of positive and negative outcomes in terms of tissue dys-
function in a randomized clinical trial. The axis marked from 0 to 168 is the time from onset
of infection. The axis marked from 0 to 1 shows the ratio of dysfunction at that time to
maximal dysfunction. (Courtesy of Dr.G.Clermont)
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3.3 APPENDIX: MODIFICATION OF THE DETAILED MODEL TO
SIMULATE ANTHRAX INFECTION
The general model (2.40) is modified to simulate anthrax infection, by removing the equation
for endotoxin pe and adding the following equations for the anthrax toxins. The mechanism
for the spore getting converted to active bacterium is also modeled. The susceptibility
parameters of the pathogen are decreased in comparison with (2.40) to model the anti-
phagocytic capsule. The effects of the toxins are captured by changing the equations for
neutrophils and TNF-α (represented by Cp in the model). Only the equations that have
been modified in some manner from (2.40) are presented here.
dSPORE
τdt
= −kspSPORE ∗Mr
dP
τdt
= kpgP (Mr +Ma − kpsP )H(P − P0)
− (kpmMa + kpNONO +KpO2O2 + kabH(t− tab))P + kspSPOREMr
dEF
τdt
= kefpP − kefEF
dLF
τdt
= klfpP − klfLF
dPAF
τdt
= kpafpP − kpafPAF
dET
τdt
= kepafEFPAF − ketET
dLT
τdt
= klpafLFPAF − kltLT
dMa
τdt
= kmpP + kmdD)(f2(Cp, θcp) +Km6f2(IL6, θ6))
fca(Ca, θca)Mr − kmaMa +Kmlt(LTMr − L2TMa) + kmspSPOREMr
dN
τdt
= (knetET + knpf(P, θ2) + kncpf(Cp, θcp) + kn6f(IL6, θ6) + kndf(D, θ2))N(1− knsN)
− (knnoNO + kNO2O2)n− kn(fS(Cp, θcp) + fs(IL6, θ6))N + Sn
dO2
τdt
= (
kO2nN
1 + ET
+ kO2mMa)(f(Cp, θcp) + k026f(il6, θ6))
+ kO2npnf(P, θ))fca(Ca, θca)− kO2O2)
dCp
τdt
= (kcpnN + kcpmrMr + kcpmMa)fca(Ca, θcpca)(1 + kcpcpf(Cp, θcp)) + kcpBOMB(kmltMaL
2
T )
− kcpCp − katnfS(tatnf , tatnf+dur, τ)Cp
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3.3.1 Parameters varied
The rate constants that are varied from the model (2.40) are as follows.
kpno 0.2 kpO2 0.2 kpm 0.2 kepaf 1.0
kefp 0.15 kef 0.5 klfp 0.15 ket 0.5
klf 0.5 kpafp 0.015 kpaf 0.5 klpaf 1.0
klt0.5 kmlt 0.05 knet 0.5 kcpbomb=1.0
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4.0 THE THRESHOLD OF EXTINCTION OF DECAYING
POPULATIONS IN A DETERMINISTIC MODEL
Ordinary Differential Equations (ODEs) are often used to model interacting populations.
In such models, deterministic behavior of continuous populations and spatial homogeneity
are assumed. Although powerful results may be obtained from the analysis of ODE models,
models that explicitly account for stochasticity and spatial distribution could result in quali-
tatively different and often more fundamental understanding of the systems studied (Durrett
& Levin, 1994; Nasell, 1995; Gandhi et al., 1998).
In particular, the extinction of a population cannot be handled using differential equa-
tions. In the ODEmodels of acute inflammation discussed in Chapter 2 immune-cells respond
to an invading pathogen and attempt to eliminate it in a manner similar to a predator-prey
model (Kumar et al., 2004b). While the pathogen population can diminish exponentially
fast when acted on by the immune-cells, it can never become completely eliminated in a
finite time. Thus a consequence is that if the immune-cells return to rest after an inflam-
matory episode, then the pathogen will re-grow from an infinitesimal quantity. This is an
artifact that arises because the approximation of pathogen population as a continuous vari-
able breaks down when the population becomes small and the discreteness of the pathogen
number becomes important. In the continuous, deterministic model, populations never go
to 0 and thus unstable cycles are seen in the phase-plane. However, in a discrete, stochastic
model, the cycles are not expected to be sustained, as fluctuations will take the populations
to zero after which there is no possibility for further dynamics. Thus, in this regime, a
stochastic or agent based model where the pathogen can be completely eliminated is more
appropriate. This problem is encountered in several ecological and other population models
and is usually handled by introducing an arbitrary low threshold for the population in the
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ODE, below which it is considered to be extinct (Williams & Martinez, 2004; Abramson
& Zanette, 1998; Yodzis & Innes, 1992). Several studies have attempted to estimate times
to extinction in population models and a detailed survey of the various approaches can be
found in Nasell (2001). The earliest and most fundamental work (Bartlett, 1966) examines
the probability distribution of a population given a birth and death rate, and estimates the
chance to extinction based on parameters in such a probabilistic model. Another study (So-
lari & Natiello, 2003) approximates the probability distribution of a population model with
a product of probabilities of independent Poisson processes and then predicts the times to
extinction and other quantities of interest. A fully probabilistic 2-dimensional model of an
epidemic of infection is simplified using conditional probability distributions and the time
to extinction can be predicted (Nasell, 1999; Nasell, 2001). Nasell (1999), also compares the
time to extinction with previous predictions.
In this chapter, the average time to extinction for a decaying population is estimated
from the probabilistic analysis of a simple 1-dimensional decay (with varying decay rates).
Using this time, an effective threshold is obtained below which the pathogen is assumed to be
extinct. The goal is to retain the ODE description to the limit of its validity and terminate it
as the description breaks down at very small numbers. The effectiveness of this threshold in
deterministic models of interacting populations is also examined. A Fokker-Planck estimate
for a threshold is also derived and found to be unsatisfactory for this problem, as suggested
by other studies (Doering & Sander, 2004). Spatial homogeneity is assumed in this analysis
and further corrections may be necessary to understand extinction in interacting populations.
4.1 THRESHOLD FOR THE GENERAL DECAY PROCESS FROM THE
MASTER EQUATION AND GILLESPIE SIMULATION
Consider a general decay process represented by :
x+ 1
k(t)→ x, (4.1)
where
k(t) ≥ 0 ∀ t. (4.2)
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Modeling this process by the differential equation dx/dt = −k(t)x, yields the solution
x(t) = x0 exp(−(g(t)− g(0))) (4.3)
where g(t) =
∫ t
0 k(t
′) dt′. In such a model x is thought to represent the average of a large
number of ensembles and x is approximated by a continuous variable. This solution suggests
that the average of an ensemble goes to zero when t→∞.
However, a more accurate representation is to consider the population x to be discrete
and the decay to be a stochastic process. Then, in principle, the statistics of the decay
process can be obtained from solving its Master equation.
We propose that the average time at which a population decays can be found from such
a discrete, stochastic model and a threshold can be computed from it that can be used as
cut-off in the continuous, deterministic model.
The Master equation for the probability distribution of x in time t for the general decay
process is as follows
dP (x, t)
dt
= k(t)[(x+ 1)P (x+ 1, t)− xP (x, t)]. (4.4)
The above equation is discrete in x and continuous in t. The solution to this equation can be
found exactly using an iterative process and induction (Appendix 4.4.1) with the condition
that P (x, 0) = δ(x, x0) where x0 is the initial population. The solution is given by
P (x, t) =
 x0
x
 exp(−(g(t)− g0))x(1− exp(−(g(t)− g0))(x0−x)). (4.5)
Now the average time this system takes to decay can be calculated as follows. P (0, t) is the
probability of the population being 0 at time t and from Equation 4.5, is given by
P (0, t) = (1− exp(−(g(t)− g0)))x0 .
Then, we define the probability density Π(0, t) that describes the fraction of particles that
go from state ‘1’ to state ‘0’ between time t and t+ dt as
dP (0, t)
dt
= Π(0, t) = k(t)x0 exp(−(g(t)− g0))(1− exp(−(g(t)− g0)))x0−1
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with the following properties:
∫ t2
t1
Π(t) dt is the fraction of particles that decay in the time
interval [t1, t2];
∫∞
0 Π(t) dt ≡ 1 because all the particles are expected to have decayed in
infinite time. In order for this normalization to be valid, we insist that
g(∞) =∞. (4.6)
So the average time 〈T 〉 it takes for the particles to decay is given by the integral,
∫ ∞
0
tΠ(t) dt = 〈T 〉. (4.7)
This can be solved by expanding (1−exp(−(g(t)−g0)))x0 in the integral as a binomial series
(Appendix 4.4.1) and 〈T 〉 is given as
〈T 〉 = x0
x0−1∑
j=0
(−1)j
j + 1
 x0 − 1
j
∫ ∞
0
exp(−(j + 1)(g(t)− g0))dt (4.8)
Similarly an expression can be found for 〈T 2〉 from which the variance can be computed.
〈T 2〉 = 2x0
x0−1∑
j=0
(−1)j
j + 1
 x0 − 1
j
∫ ∞
0
t exp(−(j + 1)(g(t)− g0))dt (4.9)
(The integral for the average time (4.7) may also be solved in an asymptotic expansion
in order to more easily determine the behavior as x → ∞ (Kumar & Chow, 2004). For
k(t) = 1, 〈T (x0 = ∞)〉 → Euler’s constant (0.5772..)) Thus the average time of extinction
and the standard deviation can be analytically calculated from the Master equation for a
general decay process with a time-dependent rate of decay. The threshold for extinction is
then the value of x in Eq. (4.3) at time t = 〈T 〉.
For instance, for the simple exponential decay process, the rate k(t) = 1, and its integral
g(t) = t satisfy conditions (4.2, 4.6). Thus the average time of extinction for this process
can be calculated from Eq. (4.8). This average time 〈T 〉 can now be used to calculate the
threshold of extinction, Θ in the solution for the continuous model, Θ(x0) = x0 exp(〈T 〉). In
Figure 4.1, thresholds computed for various rates of decay and with various initial conditions
are shown. It is interesting to note that the threshold value for different k(t) are all less than
one.
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Such stochastic processes can also be numerically simulated using the Gillespie algorithm
(Gillespie, 1977). Starting from t = 0 and x = x0, in the case of the general decay process,
the algorithm is used to generate the time at which the next particle decays based on the rate
at which the reaction can occur. A uniform random number between 0 and 1, r is generated
and the time of the next decay tn can be determined using, r = exp (−x ∫ tnto k(t)dt) where
to is the time at which the previous decay had occurred. The averaged results from several
Gillespie simulations are also shown in Fig. 4.1 and coincide with the predictions from the
Master equation.
We observe that in units of population [X], the threshold is a fraction (around 0.5) of a
particle and the stronger the killing rate, the higher the threshold. For instance, in Figure
4.1, the threshold for the strong exponential rate of killing is much higher than that for the
weak killing rate 1/(t+ ²). Also, the threshold of extinction for oscillating rates is closer to
k(t) = 1, the higher the frequency of the oscillation.
4.2 THRESHOLD FOR THE SIMPLE DECAY PROCESS FROM THE
FOKKER-PLANCK AND LANGEVIN APPROXIMATIONS
4.2.1 Fokker-Planck Equation
In the case of the decay process, the Master equation is completely solvable. However,
in general, it is intractable and approximations are necessary to solve it. Fokker-Planck
equations are obtained by approximating the “jumps” in a Master equation to be infinitely
small (van Kampen, 2003). Results from a Fokker-Planck (F-P) approximation of the Master
equation are often used to obtain the statistics of a stochastic process (Kepler & Elston,
2001).
In the case of the simple decay process, the F-P equation can be derived from the Master
equation by a Taylor expansion up to the second order that considers x to be a continuous
variable. Consider the simple exponential decay process where the decay rate k(t) = 1.
Then, the F-P equation for the probability density of x varying in t is
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Figure 4.1: Threshold of extinction for various rates of decay - as predicted by the Master
equation and Gillespie simulations. The rates k(t) are marked on the right. The Gillespie
simulations are averages of 10000 runs. (Gillespie results are shown as dotted lines. For the
sinusoidal rates k(t) = 1− sin(t) and k(t) = 1− sin(10t), the average of 1000 Gillespie runs
is shown.)
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∂P (x, t|x0, 0)
∂t
=
∂
∂x
[xP (x, t|x0, 0)] + 1
2
∂2
∂x2
[xP (x, t|x0, 0)]. (4.10)
The goal again is to obtain the average time of extinction for a species obeying the
above equation and compare it to that obtained from the Master equation. In particular,
the problem can be thought of as a first passage time problem. First passage describes how
long a particle whose position x is described by the F-P remains in a region L. In this
problem, the question posed is, what is the time T it takes for a given experiment to decay
to 0 particles and what is the average time 〈T 〉 of several such experiments? Such a mean
first passage time describes the average time to extinction.
The problem can be defined thus. Consider a population obeying the F-P equation
(4.10), which has an absorbing boundary at x = 0. At x = b, b À 0, consider another
absorbing boundary. In this problem,if the initial condition is P (x, 0) = δ(x − x0) where
x0 < b, there is no probability for the population to increase and increase past x0 to x0 = b.
The only way to leave the region is to exit at x = 0. (In Appendix 4.4.2, the same results
are derived even if x0 = b is assumed to be a reflecting boundary as long as b À 0.) Under
these conditions, the probability at time t that the population is still in the interval (0, b) is∫ b
0 dxP (x, t|x0, 0) ≡ G(x0, t)
G(x0, t) can also be thought of as the probability that the population leaves (0, b) at a
time 〈T 〉 ≥ t i.e., G(x0, t) = ∫ b0 dx′P (x, t|x0, 0) = Prob(〈T 〉 ≥ t). Then the mean first passage
time out of the region (0, b) is given by 〈T (x0)〉 = − ∫∞0 t∂tG(x0, t)dt = ∫∞0 G(x0, t)dt. It
is possible to obtain an equation obeyed by G(x0, t) and hence 〈T (x0)〉 from the backward
F-P equation (with boundary condition P (x, 0|x0, 0) = δ(x− x0)) rather than from the Eq.
(4.10) (Gardiner, 1985). Such an equation for 〈T (x0)〉 can be solved with the appropriate
boundary conditions (in this case 〈T (0)〉 = 〈T (b)〉 = 0 (Appendix 4.4.2)) and an expression
can be obtained for the mean time for a population decaying at the rate k(t) = 1 to reach
x = 0. This is given by
〈T (x0)〉 = −2 exp(2x0)I(x0, b)− 2I(0, b), (4.11)
where I(p, q) is defined as
∫ q
p exp(−2x′) ln(x′)dx′.
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The above expression for 〈T (x0)〉, Eq. (4.11) can be computed numerically for vari-
ous initial conditions x0 (by assuming b to be a very large number). Results from such a
calculation are shown in Figure 4.2 and are compared with the thresholds obtained from
considering the full stochastic process using the Master equation. The threshold from the
F-P approximation is much higher than that of the Master equation. This indicates that the
F-P description is not a good approximation to determine extinction times.
4.2.2 Langevin Equation
Another simplification in capturing stochastic behavior is the Langevin approach. Here,
the macroscopic behavior of the process is assumed to be known and stochastic effects are
introduced by adding a ’noise source’ to the equation of motion (under the restriction that
the stationary solution reproduces the correct mean square fluctuations known from the
dynamics of the problem) (van Kampen, 2003). Though, in general, the Langevin equation
has to be derived systematically from the F-P equation, for the simple decay process the
equation is given by,
dx/dt = −x+√xL(t), (4.12)
where the properties of L(t) are: its mean ∫ L(t′)dt′ = 0 and its auto-correlation function∫∞
−∞ L(t)L(t + τ)dτ = δ(τ). It can be proved that the statistics represented by Eq. (4.12)
are the same as those of Eq. (4.10) when the Itoˆ rule is used to interpret Eq. (4.12) (Page.
230-236 (van Kampen, 2003)).
The stochastic differential equation (4.12), can be evolved numerically where L(t) is a
implemented by generating a random number with a Gaussian distribution (mean=0, vari-
ance=1). The average time to extinction can thus be obtained from the Langevin equation
and can be used to estimate a threshold as well. These results are also plotted in Figure
4.2. Thus converting the deterministic ODEs to Langevin equations by adding noise terms
is also not an accurate method to model stochastic processes.
Though the Langevin and F-P approximations are routinely used to obtain the statistics
of a stochastic process, they should be used cautiously, as these examples demonstrate.
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Figure 4.2: Time of extinction for decay process with rate k(t)=1 using the various methods.
(Results from Gillespie and Langevin methods are shown as dotted lines.)
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4.3 THRESHOLD OF EXTINCTION FOR LARGER MODELS
The aim of the above analysis was to predict an estimate for the threshold of extinction
for deterministic population models, below which the population may be considered to be
extinct. Can the threshold predicted by the general decay process be used as a “cut-off” for
a general population model?
We tested our predictions by implementing the numerical Gillespie simulation of the
modification of the 2 dimensional model (represented by the ODE system (2.1,2.3) in Chapter
2) that captures pathogen- immune-cell dynamics. The reactions which constitute the model
are as follows:
p
k1→ 2p (4.13)
p+m
k2→ 2m (4.14)
m
k3→ ∅ (4.15)
m+m
k4→ 3m (4.16)
This is a stochastic simulation that models the fate of individuals in a population - hence
p and m are measured as numbers of cells with dimensions, say [X] (pathogens or immune-
cells). The first reaction (4.13) describes a pathogen dividing into 2 at the rate k1. k1 has
the units of inverse time 1/[T ]. Reaction (4.14) describes the interaction between a pathogen
and an immune-cell. At the rate k2, when a p meets an m, the p dies and a new m is created.
The rate k2 has dimensions 1/([T ][X]). Reaction (4.15) describes an immune-cell decaying
at the rate k3 where the dimensions of k3 are also 1/[T ]. Reaction (4.16) represents the
positive feed-back of immune-cells at the rate k4 where k4 has units 1/([T ][X]).
In implementing a stochastic simulation of the above interactions, detailed balance is im-
plicitly assumed. (Technically detailed balance is defined as the condition that in stationary
state the probability of going from state n to n′ is the same as the probability of the opposite
transition from n′ to n i.e. p(n)W (n, n′) = p(n′)W (n′, n), where p(x) is the probability to
be in state x and W (x, x′) is the transition probability from x to x′ (van Kampen, 2003).
This is not necessarily the case in an ODE system).
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Another consideration while implementing a stochastic simulation is that outcomes that
are not expected deterministically can also occur. For instance, in the above simulation, the
pathogen is expected to grow, followed by growth in immune-cells. But chance fluctuations
could result in the initial population of immune-cells to decay and the pathogen to grow at an
exponential rate. Thus, although a deterministic model of the system predicts oscillations,
in stochastic simulations, the pathogen and immune-cells go through a growth-death cycle
at the end of which there is a high probability that the pathogen becomes extinct and the
immune-cells also decay away.
A Gillespie algorithm is set up to simulate (4.13-4.16) (Gillespie, 1977). A random
number is generated to determine the time of the next interaction and another random
number is generated to determine which of the interactions occurs (based on the rate of each
reaction). For the 2 random numbers r1 and r2, the time at which the next reaction occurs
is,
tn = to + (1/k0)ln(1/r1)
where to is the time at which the previous interaction has occurred and k0 is the sum of the
(time-independent) rates of the 4 reactions, k0 =
∑4
µ=1 kµ. The interaction to be simulated
is the µth interaction for which
∑µ−1
j=1 kj < r2k0 ≤
∑µ
j=1 kj.
The simulations are carried out for various initial conditions and parameters (k1,k2,k3,k4)
and the times to extinction are recorded. Now, the question arises, how is this time translated
into a threshold for an ODE model? In the case of exponential decay, the predicted time of
extinction was simply plugged into the solution for the ODE and a threshold was obtained.
This should be done more carefully in the case of a more complicated model. The reactions
(4.13-4.16) can be modeled using the following equations.
dp
dt
= k1p− k2mp (4.17)
dm
dt
= k2mp− k3m+ k4m2, (4.18)
In general an ODE models the concentrations of the populations in question and it can
be scaled to different units. Thus, p and m have dimensions of particle/volume or [X]/[V ].
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The parameters k1 and k3 still have dimensions 1/[T ] and can be identified exactly with the
corresponding parameters in the discrete simulation (as long as the time scales are the same).
Parameters k2 and k4 however reflect the scale as they have dimensions [V ]/([T ][X]) and
have different numerical values depending on the scale at which the ODE model is chosen.
(Note that k2 is the rate at which the pathogens are killed and also the rate at which the
immune-cells are created as a consequence of detailed balance.)
So to connect the stochastic and the deterministic model, a volume scale [V ] is chosen,
say V = 1ml. The rate constants and initial conditions are scaled accordingly and supplied
to the Gillespie simulation, say p(0) = p0,m(0) = m0. Now, if a different scale were to be
chosen for the same ODE model, say V = 2ml, representing the same underlying biology
(same growth rates, initial concentrations, interactions etc.), then the scaled initial conditions
and parameters are supplied to the Gillespie algorithm (in this case, at double the volume
and the same concentration, the initial conditions are p(0) = 2p0,m(0) = 2m0 and k2 and
k4 are half that of the previous experiment.) As can be expected, stochastic simulations
performed in larger volumes more closely mimic continuous models. (The above argument
is not restricted even if the ODE does not model concentration but scales the population in
any other general dimension. [V ] could be an area, length or even non-dimensional).
Keeping the above considerations in mind, a threshold is calculated by plugging the
extinction times predicted by the Gillespie algorithm into the ODE. These thresholds are
then compared to those predicted from the general one dimensional decay processes (Figure
4.3). We observe that they tend to lie within the range of error of thresholds predicted by
the Master equation for a general decay process with decay rate k(t) = exp(t) in Section 4.1.
(The error from the Master equation is in the time of extinction and is expanded to first
order to find the error in the threshold.)
It is not entirely surprising that the thresholds of extinction for (4.17,4.18) tend to the
extinction threshold for k(t) = exp(t), as the rate at which p is killed is k2mp andm is growing
at an exponential rate when p is present. Thus a prediction from the Master equation of the
threshold of extinction of a general decay process is a good estimate to determine when the
population in a larger dimensional continuous model should be considered extinct.
The distribution of the thresholds of extinction, F(Θ) from the Master equation for a
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given rate of decay (k(t)) can be specified by the mean and standard deviation as in Fig. 4.3.
An algorithm can be devised, where the threshold is a random number θ, generated with a
(Gaussian) distribution F(Θ), for every time-step of an ODE evolution. If the population
value of the ODE is below θ, the evolution of the ODE is stopped and if not, the next
time step is computed. Such an algorithm could in principle capture extinction and even
oscillations that may occur stochastically.
In many respects, the conclusions of this analysis are fairly intuitive. Deterministic
models capture average behaviors of the actual stochastic process. We predict the time at
which more than half of the possible experiments would have become extinct from a stochastic
model and use that to cut off the deterministic simulation. Instead of choosing arbitrarily
low thresholds to cut-off simulations as is often done, if the scales in the ODE are understood,
simulations may be safely stopped when the population numbers are approximately 1/2 in
the scales chosen.
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Figure 4.3: Threshold from Gillespie simulation of 2-d models with varying parameters
compared with predicted values (for k(t) = 1 and k(t) = exp(t)) from the Master equation.
The inverted triangles represent the parameter set k1 = 0.5, k2 = 1.0, k3 = 0.1 and k4 = 0.01.
The circles represent the parameter set where there is no feed-back to m i.e. k4 = 0. The
other parameters are k1 = 1.0, k3 = 0.1 and k2 is 1.0 (filled) and 2.0 (unfilled). The scale
for all simulations: ODE is 1/500 times that of the Gillespie.
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4.4 APPENDIX
4.4.1 〈T 〉 from the Master Equation
The Master equation for a general decay process is given by Eq. 4.4,
dP (x, t)
dt
= k(t)[(x+ 1)P (x+ 1, t)− xP (x, t)]. (4.19)
This equation needs to be solved with the following boundary condition, P (x, 0) = δx,x0
and P (x0 + 1, t) = 0. From Eq. (4.19), P (x0, t) can be obtained as follows,
dP (x0, t)
dt
= −k(t)x0P (x0, t)⇒ P (x0, t) = exp(−x0(g(t)− g0)),
where g(t) =
∫
k(t′)dt′. Now, from (4.19), the equation obeyed by P (x0 − 1, t) is as follows:
dP (x0 − 1, t)
dt
= k(t)[x0P (x0, t)− (x0 − 1)P (x0 − 1)
with solution
P (x0 − 1, t) = x0 exp((x0 − 1)(g(t)− g0))[1− exp(g(t)− g0)].
We can prove by induction that the solution of P (n, t) is
P (n, t) =
 x0
n
 [exp(−(g(t)− g0))]n[1− exp(−(g(t)− g0)]x0−n, (4.20)
and show that the solution for P (n−1, t) has the same form as P (n, t). The equation obeyed
by P (n− 1, t) if Eq. (4.20) is true, is
dP (n− 1, t)
dt
=
k(t)[(n
 x0
n
 [exp(−(g(t)− g0))]n[1− exp(−(g(t)− g0))]x0−n)− ((n− 1)P (n− 1, t))].
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Moving the P (n − 1, t) term to the left hand side, and multiplying both sides by the
integrating factor exp(g(t)(n− 1)) and combining, we get
d(P (n− 1, t)(exp(g(t)(n− 1))))
dt
=
k(t)(n
 x0
n
 [exp(−(g(t)− g0))]n[1− exp(−(g(t)− g0))]x0−n) exp(g(t)(n− 1)).
Now, integrate both sides with respect to t. The right hand side can be integrated by
parts by assuming, say y = 1− exp(g(t)− g0), so the equation reduces to
P (n− 1, t) exp((g(t)(n− 1)) = n
 x0
n
 exp((n− 1)g0) ∫ yx0−ndy.
Integrating and re-arranging, we get,
P (n− 1, t) =
n
x0 − n+ 1
 x0
n
 exp((n− 1)g0) exp(−(g(t)(n− 1)))[1− exp(−(g(t)− g0))]x0−n+1
+ C exp(−g(t)(n− 1)),
where C is the constant from integration. Now, applying the boundary condition that
P (n− 1, 0) = 0 (because at t = 0, P (x, 0) = δ(x, x0)) ⇒ C = 0.
Simplifying, we get,
P (n− 1, t) =
 x0
(n− 1)
 [exp(−(g(t)− g0))]n−1[1− exp(−(g(t)− g0))]x0−n−1
which is the same as the form for the solution of P (n, t), Eq. (4.20).
Now, that the solution for the Master equation is known, we proceed to find the average
time of extinction. The probability distribution that the population goes to 0 in the time
interval between t and t+ dt, Π(t) is given by
Π(t) =
dP (0, t)
dt
=
x0k(t)[1− exp(−(g(t)− g0))]x0−1 exp(−(g(t)− g0)).
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The average time to extinction is then given by
∫∞
0 t
′Π(t′)dt′ under the condition that∫∞
0 Π(t
′)dt′ ≡ 1.
The normalization condition for Π(t) can be proved thus.∫ ∞
0
Π(t′)dt′ =
∫ ∞
0
k(t′)[1− exp(−(g(t′)− g0))]x0−1 exp(−(g(t′)− g0)).
Set y = 1− exp(−g(t′)− g0), then,∫ ∞
0
Π(t′)dt′ = x0
∫ 1
0
yx0−1dy
= 1.
The limits can be set as above and the function normalized only under the following condi-
tion: g(∞) =∞ as specified by Eq. (4.6).
Next, we derive an expression for average T , 〈T 〉 where
〈T 〉 =
∫ ∞
0
t′Π(t′)dt′.
Substituting the expression for Π(t), we get,
〈T 〉 = x0
∫ ∞
0
t′x0k(t′)[1− exp(−(g(t′)− g0))]x0−1 exp(−(g(t′)− g0)).
Expanding [1− exp(−(g(t′)− g0))]x0−1 as a binomial series and taking the summation sign
out of the integration sign,
〈T 〉 = x0
x0−1∑
j=0
−1j
 x0 − 1
j
∫ ∞
0
t′k(t′) exp(−g(t′)− g0)dt′
Integrating by parts by setting t′ = u and k(t′) exp(−(j + 1)(g(t′) − g0))dt′ = dv, and
substituting the condition (4.6),
〈T 〉 = x0
x0−1∑
j=0
−1j
j + 1
 x0 − 1
j
∫ ∞
0
exp(−(j + 1)(g(t′)− g0))dt′.
Similarly, integrating by parts twice, we get,
〈T 2〉 = 2x0
x0−1∑
j=0
(−1)j
j + 1
 x0 − 1
j
∫ ∞
0
t′ exp(−(j + 1)(g(t′)− g0))dt′.
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4.4.2 〈T 〉 from the Fokker-Planck Equation
Calculating the average time of extinction from the F-P equation closely follows the method
explained in Page.136-138 of (Gardiner, 1985). The F-P equation obeyed by a population of
decaying particles is given by Equation 4.10,
∂P (x, t|x0, 0)
∂t
=
∂
∂x
[xP (x, t|x0, 0)] + 1
2
∂2
∂x2
[xP (x, t|x0, 0)].
Let the initial population at time t = 0 be x = x0. The question is how long does the
population remain in the interval (0, b) which contains x, such that 0 ≤ x0 ¿ b. We assume
that 0 and b are absorbing boundaries (for now). Under these conditions, the probability that
at time t, the particle is still in (0, b) is given by
∫ b
0 dxP (x, t|x0, 0) ≡ G(x0, t) (i.e. starting
at x = x0 at t = 0, integrate over the probability of being at any x such that 0 ≤ x ¿ b).
G(x0, t) can also be thought of as probability that the population leaves (0, b) at a time
T ≥ t i.e., G(x0, t) = ∫ b0 dxP (x, t|x, 0) = Prob(T ≥ t). Since the system is homogeneous in
time, the backward F-P equation can be written using the same boundary (initial) condition
P (x, t|x0, 0) = P (x, 0|x0,−t) so that,
∂P (x, t|x0, 0)
∂t
= x0
∂P (x, t|x0, 0)
∂x0
+
1
2
x0
∂2P (x, t|x0, 0)
∂x02
.
Integrating the backward F-P with respect to x (which is not as trivial in the forward F-P),
we get
∂G(x0, t)
∂t
= x0
∂G(x0, t)
∂x0
+
1
2
x0
∂2G(x0, t)
∂x02
, (4.21)
obeyed by G(x0, t). Now, the boundary conditions are
P (x, 0|x0, 0) = δ(x− x0)
and hence,
G(x0, 0) = 1 when 0 ≤ x0 ≤ b
G(x0, 0) = 0 elsewhere and
G(0, t) = G(b, t) = 0.
Now, the mean first passage time out of the region (0, b) is given by
〈T (x0)〉 = −
∫ ∞
0
t∂tG(x0, t)dt =
∫ ∞
0
G(x0, t)dt,
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and obeys the following equation which is obtained by integrating 4.21 from 0 to ∞ with
respect to t:
x0
∂〈T (x0)〉
∂x0
+
1
2
x0
∂2〈T (x0)〉
∂x02
= −1. (4.22)
(This result uses the fact that G(x0,∞) = 0 and G(x0, 0) = 1.) Now for the absorbing
boundaries, T (0) = T (b) = 0.
Equation 4.22 can be re-arranged as
∂2〈T (x0)〉
∂x02
− 2∂〈T (x0)〉
∂x0
= − 2
x0
.
⇒ 〈T (x0)〉 = −D exp(2x0)− 2 exp(2x0)I(0, x0) + C
2
(exp(2x0 − 1))
where C and D are constants of integration and
I(p, q) ≡
∫ q
p
exp(2x′) ln(x′)dx′.
Applying boundary conditions,
〈T (0)〉 = 0⇒ D = 0
〈T (b)〉 = 0⇒ C = 4 exp(2b)I(0, b)
exp(2b)− 1
⇒ 〈T (x0)〉 = −2 exp(2x0)I(0, x0) + 2 exp(2b)I(0, b)
exp(2b)− 1 (exp(2x0 − 1)
Substituting I(0, b) = I(0, x0) + I(x0, b) and limb→∞
exp(2b)
exp(2b)−1 = 1,
〈T (x0)〉 = −2 exp(2x0)[I(0, b)− I(x0, b)] + 2I(0, b)(exp(2x0 − 1))
⇒ 〈T (x0)〉 = 2 exp(2x0)I(x0, b)− 2I(0, b)
The above analysis assumes two absorbing boundaries where the boundary at b is only an
approximation because physically there is no absorbing boundary. Here, we prove that even
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if b is assumed to be a reflecting boundary, the expression for 〈T 〉 remains the same. Equation
(4.22) is now solved with the boundary conditions 〈T (x0 = 0)〉 = 0 and ∂〈T (x0=b)〉∂x0 = 0.
〈T (0)〉 = 0⇒ D = 0
∂〈T (x0 = b)〉
∂x0
= 0⇒ C = 4I(0, b) + 2 exp(−2b) ln(b)
⇒ 〈T (x0)〉 = −2 exp(2x0)I(0, x0) + (2I(0, b) + (exp(2x)− 1))
Substituting I(0, b) = I(0, x0) + I(x0, b) and limb→∞ exp(−2b) ln(b) = 0,
⇒ 〈T (x0)〉 = 2 exp(2x0)I(x0, b)− 2I(0, b).
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